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ABSTRACT 
Infectious diseases cause millions of deaths every year worldwide, resulting also in 
overwhelming direct and indirect costs. Thus, they represent a major problem in primary 
human health care. In this regard, vaccination is one of the most cost-efficient strategies 
for their prevention. Successful vaccines should be highly effective in evoking immune 
responses able to protect against specific pathogens while at the same time leading to 
negligible adverse reactions. To circumvent safety issues associated with the use of 
whole pathogen containing vaccines, the development of vaccines containing pathogen 
subunits should be favored. However, they are usually poorly immunogenic, making 
necessary to incorporate adjuvants in the formulation. The cyclic di-nucleotides (CDNs) 
bis-(3´,5´)-cyclic dimeric guanosine monophosphate (c-di-GMP) and bis-(3´,5´)-cyclic 
dimeric adenosine monophosphate (c-di-AMP) are promising candidate adjuvants, 
capable of enhancing the stimulation of balanced humoral and cellular immune 
responses after systemic or mucosal administration. However, their immune regulatory 
properties and their molecular mode of action remain to be fully characterized as a 
precondition for their application in vaccines leading to predictable immune responses in 
humans. 
In the first part of this thesis, the mucosal adjuvant activity of the newly discovered CDN 
(3',5'-3',5')-cyclic (adenosine monophosphate-guanosine monophosphate) (cGAMP) 
was demonstrated in mouse immunization studies and was compared to the adjuvant 
activity of c-di-AMP to identify possible differences in their immune stimulatory potency. 
Based on immunization experiments using ovalbumin as model antigen, it was shown 
that c-di-AMP and cGAMP enhance the stimulation of antigen-specific humoral 
responses (e.g. mucosal IgA and systemic IgG), T helper (Th) 1 and Th2 responses to a 
similar extent. In contrast, c-di-AMP was shown to be a stronger enhancer of the Th17 
response, as compared to cGAMP. In vitro experiments using bone marrow derived 
dendritic cells also demonstrated a stronger induction of IL-12/IL-23p40 by c-di-AMP 
than by cGAMP, whereas their capacity to up-regulate the surface expression of the 
activation markers MHC class II, CD86 and CD80 were similar. 
It is known that CDNs induce the production of cytokines (e.g. type I interferon (IFN) and 
tumor necrosis factor (TNF)-α) via the stimulator of interferon genes (Sting). The 
downstream signaling of type I IFN is mediated by the IFN-α/-β receptor (IFNAR). In the 
second part of this thesis, the relevance of the type I IFN induction and signaling 
pathways for the adjuvanticity of c-di-AMP and cGAMP was evaluated in vivo. To this 
 Abstract 
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end, immunization studies were performed using mice lacking functional Sting or IFNAR 
and the immune responses were compared to the response in wild type animals. The 
results suggested that the adjuvanticity of c-di-AMP and cGAMP is dependent on Sting, 
whereas the function of IFNAR is dispensable.  
The findings described in this thesis demonstrate the potential of CDNs to be used in 
vaccine formulations as a tool for evoking effective and predictable immune responses. 
In addition, they shed light on the role played by type I IFN signaling in the development 
of adaptive immune responses post vaccination. First, IFNAR deficiency did not abolish 
the enhancement of adaptive immune responses by c-di-AMP or cGAMP, thereby 
indicating that type I IFN is dispensable for the adjuvant efficacy of c-di-AMP or cGAMP. 
Instead, IFNAR signaling seems to modulate the extent of c-di-AMP and cGAMP-
enhanced immune responses. Second, the results demonstrate that not the classically 
described function of Sting in the induction of type I IFN but rather alternative pathways 
are required for the adjuvant activity of c-di-AMP and cGAMP. To this end, the CDN-
induced NF-κB-TNF-α signaling axis that is known to play a role in the adjuvanticity of c-
di-GMP may be considered as a possible alternative pathway. 
 
   
 Introduction 
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1 INTRODUCTION 
1.1 The immune system 
The immune system of mammals is composed of organs, tissues, cells and molecules 
that form a complex network evolutionary developed to fight dangerous entities, such as 
infectious agents and transformed cells. There are two branches of the immune system: 
the innate and the adaptive immunity. Each branch contains humoral and cellular 
components, as shown in figure 1, and acts via many mechanisms protecting the host 
from for example, colonization and/or invasion by pathogens, as well as the subsequent 
progression of infections. 
 
Figure 1: Components of the immune system. Each of the branches, innate and adaptive 
immunity is composed of cellular and humoral components that differ based on their effector 
characteristics and the pattern of their surface receptors expression. γδ T cells and natural killer 
T cells are classified as cells that bridge the innate and adaptive immunity because they not only 
show characteristics of innate cells, but as well express antigen-specific receptors (modified from 
[1]). 
    Introduction 
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1.1.1 The innate immune system 
The innate immune system is enrolled in the immediate early phase of a pathogen 
encounter. Its effector strategies are not antigen-specific and do not develop long lasting 
memory. The main components of the humoral innate immune response are proteins of 
the complement system (CS). There are several cascades of CS activation, which 
results in activation of C3 convertase, leading to different effector strategies of pathogen 
clearance. For example, once triggered by binding of e.g. C1q to the surface of a 
pathogen, CS activation triggers the enzymatic activity of C3 convertase, generating 
C3a and C3b proteins. C3a acts as a local pro-inflammatory molecule and C3b binds to 
the pathogen surface, labeling it for destruction by antigen presenting cells (APCs). 
APCs express complement receptor (CR) C3b on their surface. They recognize C3b 
bound to the surface of pathogens, resulting in elimination of these immune complexes, 
in a process called opsonization. In a similar fashion, due to surface expression of Fc 
receptors, APCs can recognize immune complexes of antibodies bound to pathogens, 
allowing their clearance [2]. 
Major cell types acting at this level of immunity are macrophages and dendritic cells, 
which function as APCs. They are required for the elicitation of adaptive immune 
responses [3, 4] and can be activated by pathogen associated molecular patterns 
(PAMPs) such as pathogen specific proteins, lipids, carbohydrates and deoxyribonucleic 
acid (DNA) or ribonucleic acid (RNA) molecules. They recognize PAMPs via specific 
pathogen recognition receptors (PRRs) expressed at the cell surface or in intracellular 
compartments. Major families of PRRs are: Toll-like receptors (TLRs), retinoic acid-
inducible gene (RIG)-like receptors (RLRs), nucleotide binding domain (NOD)-like 
receptors (NLRs), and C-type lectins [5, 6]. APCs endocytose the encountered antigens, 
digest and load their peptides on major histocompatibility complex (MHC) class II 
molecules, forming immune complexes recognized by T cells. In addition, dendritic cells 
can act as a delivery vehicle of intact antigens to naïve B cells, for example via CR1/2-
mediated surface binding of immune complexes containing antigens and complement 
components [7-9]. Activation of APCs by PAMPs enhances the surface expression of 
the MHC class II molecules and the co-stimulatory molecules cluster of differentiation 
(CD)80 (B7-1) and CD86 (B7-2). Once activated, APCs also start producing pro-
inflammatory cytokines [6, 10] and migrate to lymph nodes to activate specific T or B 
cells. 
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1.1.1.1 Type I interferons 
Type I interferons (IFNs) (IFN-α1-13, IFN-β) are important cytokines produced early after 
pathogen encounter and PAMP-mediated activation of APCs. Tank binding kinase-1 
(TBK-1) and the transcription factors IFN regulatory factor (IRF) 3 and IRF7 are the 
central players of pathways mediating IFN-α and/or IFN-β production. TBK-1 activates 
IRF3/IRF7 by phosphorylation, which triggers their dimerization and translocation to the 
nucleus where they bind to type I IFN promoters [2]. Depending on the type of PAMP, 
the IRF-mediated activation of type I IFN promoters can be enhanced by nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB), strengthening the up-regulation 
of type I IFNs [11-13] . The TBK-1-IRF3/IRF7 axis can be triggered by various PAMPs 
that are recognized by for example foreign double stranded (ds) DNA sensors, such as 
DNA-dependent activator of IFN-regulatory factors (DAI), IFN-inducible myeloid 
differentiation transcriptional activator (IFI16), DEAD (Asp-Glu-Ala-Asp) box polypeptide 
41 (DDX41) and cyclic GMP-AMP synthase (cGAS) [14-18] or by different TLR 
receptors. These molecules recruit adaptors, such as stimulator of interferon genes 
(Sting), TIR-domain-containing adapter-inducing interferon-β (Trif) or myeloid 
differentiation primary response gene 88 (MyD88) that recruit TBK-1 resulting in the 
activation of IRF3/IRF7-mediated IFN-β up-regulation (figure 2).  
 
Figure 2: Activation of the IFN-β promoter. The central activator of the IFN-β promoter is the 
TBK-1 and IRF3/IRF7 mediated signaling axis and NF-κB can enhance the activation of IFN-β 
production. Various PAMPs, such as dsDNA, dsRNA and lipopolysaccharide (LPS) are 
recognized by different sensors (DAI, IFI16, DDX41, cGAS, TLR3, TLR4). This results in 
activation of adaptor proteins such as Sting, Trif and MyD88, which recruit the TBK-1 and NF-κB, 
thereby resulting in activation of IFN-β expression. 
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Type I IFNs signal via the Interferon-α/β receptor (IFNAR)1/2, which is expressed in all 
cell types [19, 20], and activate the Janus kinase/signal transducer and activator of 
transcription (Jak/Stat) signaling cascade. As a result, IFN stimulated genes (ISGs) are 
induced, which are crucial for the establishment of antiviral responses at the cellular 
level [2] (figure 3).  
  
Figure 3: Type I IFN-associated pathways. APCs sense pathogens via detection of PAMPs. 
Type I IFNs production can be upregulated for instance upon PAMP-triggered Sting activation. 
Type I IFNs are secreted and bind to the IFNAR, which triggers Stat1/Stat2-mediated activation 
of ISGs, thereby inducing antiviral activity. 
 
1.1.1.2 Sting 
Sting (also known as ERIS, MYPS, MITA, TMEM173 and NET23) is a transmembrane 
protein located predominantly in the endoplasmic reticulum (ER) [21, 22]. Once 
activated, Sting oligomerizes, traffics from ER to perinuclear vesicles via the Golgi 
apparatus and interacts with TBK-1 that is recruited from the cytoplasm [21-23]. This 
can result in activation of transcription factors IRF3 or NF-κB, which translocate to the 
nucleus and induce IFN-β and/or tumor necrosis factor (TNF)-α production [21, 24, 25]. 
In addition, Sting can activate extracellular signal-regulated kinases (ERK) [26] and 
Stat6 [27]. Sting-mediated IFN-β production is under control of different regulators that 
induce Sting degradation [28], and affect its dimerization [29] or translocation to the 
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perinuclear region [30, 31]. There are several stimuli for Sting activation, such as: i) 
activation of cytosolic sensors of foreign dsDNA (e.g. DAI, IFI16, DDX41 and cGAS, see 
chapter 1.1.1.1) and ii) cell membrane fusion-related signals [32]. In addition, some 
cytosolic DNA sensors produce molecules that activate Sting. For example, the 
mammalian enzyme cGAS after binding of cytosolic dsDNA catalyzes the production of 
(2',5'-3',5')-cyclic (adenosine monophosphate-guanosine monophosphate) ((2’,5’)-
cGAMP). (2´,5´)-cGAMP is a non-canonical cyclic di-nucleotide so far described only in 
eukaryotes. Once produced, it binds to Sting and induces IFN-β production [17, 18, 33-
36]. Most of the reports are focused on Sting as a central molecule in the induction of 
type I IFNs and point to its role in the early immune response against pathogens. 
However, the fine regulation of Sting activity and its role in the development of an 
adaptive immune response still remain to be elucidated. 
1.1.2 The adaptive immune system 
The adaptive immune response can fight pathogens by: i) antibodies targeting the 
antigens outside the host cells and ii) cell-mediated killing of the infected host cells, 
resulting in a strong specific reaction against the pathogen and formation of memory 
cells, ensuring a long-term protection. The adaptive immune system is principally 
composed of T and B lymphocytes that recognize specific pathogens. T and B 
lymphocytes are characterized by the surface expression of T and B cell receptors, 
respectively. The variability of T and B lymphocyte receptors results from recombination 
in germ-line genes during their development. T lymphocytes acting exclusively in the 
adaptive immune response are T helper (CD4+) cells and cytotoxic (CD8+) T cells. CD4+ 
T helper (Th) lymphocytes regulate cellular and humoral adaptive immune responses, 
whereas CD8+ cytotoxic T lymphocytes (CTL) are effectors of cell mediated killing of 
infected cells. B cells mediate humoral adaptive immune responses by antibody 
production [2].  
Activation of naïve antigen-specific T cells requires two signals, which are only present 
upon activation of the APC with PAMPs to prevent unnecessary T and B cell activation 
by presented self-antigens [37]. The first signal is the binding of an antigen presented by 
MHC class II for CD4+ cells or MHC class I for CD8+ cells to a corresponding T cell 
receptor (TCR) on the surface of a T cell. The second is the co-stimulatory signal, 
provided by the interaction of CD80 and CD86 at the surface of APCs with the co-
receptor CD28 on the surface of T cells [38]. Beyond these main players, there are 
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several other surface molecules involved in fine-tuning the interaction between APCs 
and T cells, which from part of the so-called immune synapsis [39-41]. In addition, the 
activation of naïve antigen-specific T cells is supported by the local cytokine milieu 
originating from APCs and T cells [2].  
Naïve B cells process antigens in a manner similar to other APCs. The intact antigens 
may be taken directly from the environment or can be delivered by dendritic cells to 
naïve B cells [8, 42, 43]. Naïve B cells express on their surface immunoglobulin (Ig)M 
and IgD, which act as antigen receptors. After the antigen is recognized by those 
receptors it becomes endocytosed and digested. Its peptides are loaded to MHC class II 
molecules and are transported to the surface of B cells where they can be recognized by 
Th2 cells. Then the interaction of CD40 on the B cell surface and CD40L on the surface 
of the interacting T cell provides the co-stimulatory signal [44]. This triggers the 
development of B cells to antibody-producing plasma cells. There are five classes of 
antibodies: IgD, IgM, IgG, IgA and IgE. After the first encounter with a pathogen, plasma 
cells produce the IgM isotype which forms pentamers and is characterized by its low 
affinity binding to an antigen. However, B cells can undergo a class switch, leading to 
the production of high affinity IgG and IgA subclasses, which is regulated by other APCs 
and Th cells [8, 45-47]. Systemic humoral responses are characterized by IgG 
production, in mice present in a form of isotypes IgG1, IgG2a-c and IgG3, whereas IgA 
secretion is the hallmark of mucosal antibody-mediated protection [2]. Secretory IgA 
exists in a form of at least two IgA molecules, which are connected through the short J-
chain polypeptide [48, 49]. The J-chain polypeptide in a complex with IgA is recognized 
by the secretory component (SC), a protein located at the basolateral surface of 
secretory epithelial cells [50]. Binding of this ligand to SC triggers transcytosis, resulting 
in a transport of the secretory IgA from basolateral side of epithelium to the mucosal 
surface [51]. Despite the fact that secretory IgA is the major mucosal Ig, monomeric IgA 
and some other Ig subclasses originating from serum can be found at mucosal sites due 
to transudation and the proportions of different Ig subclasses there differ according to a 
specific mucosal territory [52-54].  
Activation of naïve T cells results in T cell proliferation, enhancement in their surface 
expression of adhesion molecules and promotes cell survival. The local cytokine milieu 
provides signals that promote differentiation into different CD4+ effector T cell 
phenotypes, such as Th1, Th2, Th17 or regulatory T cells [55]. For example, IFN-γ and 
interleukin (IL)-12 produced by activated APCs have been described as important  
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cytokines that promote the differentiation of CD4+ effector T cells into the Th1 phenotype 
[45, 56]. Th1 cells are characterized by IFN-γ and IL-2 production leading to the 
development of a CTL response. CTL induce apoptosis of infected cells by different 
mechanisms (e.g. granzyme release into target cells, binding of Fas ligand on the 
surface of CTL to Fas receptor on the target cell) [57-61]. This is important for clearing 
infections caused by intracellular pathogens, such as viruses, Toxoplasma gondii [62] or 
certain fungal infections [63]. Increased IL-4 and decreased IFN-γ production by APCs 
and B cells [64] promote CD4+ T cell differentiation into the Th2 phenotype. These cells 
are characterized by IL-4 production and promote the adaptive humoral immune 
response. This branch of the immune response is important for resolving infections 
caused by extracellular pathogens, such as some extracellular bacteria and helminths 
[65]. Activation of naïve CD4+ T cells in the presence of IL-6, IL-21, IL-1β and 
transforming growth factor (TGF)-β results in differentiation into the Th17 phenotype [66, 
67], which is maintained by APC-secreted IL-23 [68, 69]. CD4+ T cells of the Th17 
phenotype secrete IL-17A, IL-17F, IL-21 and IL-22 [70] and are indispensable to fight 
extracellular pathogens, such as Klebsiella pneumoniae [71]. Taken together, relative 
amounts of different cytokines induced by a pathogen modulate the differentiation of 
naïve T cells and therefore the profile of the final adaptive immune response [2]. 
1.2 Mucosal vaccination 
Infectious diseases are one of the major health problems worldwide, being directly 
responsible for millions of deaths every year [72, 73]. Pathogens use various strategies 
to colonize human hosts and cause diseases [74-78]. Treatment of infections is 
rendered difficult by the lack of highly effective drugs against many agents (e.g. Ebola 
virus, influenza), as well as the rapid emergence and spread of anti-microbial resistant 
strains [79]. Thus, vaccination remains as one of the most effective prevention strategy 
to fight infections. In addition, the potential use of vaccines as a therapeutic tool against 
infections has also gained considerable interest [80]. However, there are still many 
infections for which there is no available vaccine or the existing vaccine is suboptimal 
[81]. This is particularly true for diseases in which the simulation of cellular immunity 
would be needed in order to confer efficient protection. Therefore, new vaccines able of 
promote long-term protection are urgently needed. Most pathogens are restricted to or 
need transit across the mucosal barriers (e.g. gastrointestinal, respiratory and urogenital 
mucosa) [82]. Therefore, ensuring local pathogen-specific immune protection at the  
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mucosa would be advantageous for controlling the pathogen early upon the encounter 
with the host. However, most of the currently available parenterally administered 
vaccines elicit mainly systemic responses, while they are less effective at mucosal sites 
[83]. The mucosal administration of vaccine antigens induces not only systemic immune 
response, but also a mucosal response at the pathogen´s port of entry [84, 85].  
1.2.1 Basic principles of mucosal immune responses 
The local mucosal immune response against infections is based on unspecific 
mechanisms of defense and pathogen-specific immune responses largely mediated by 
secretory IgA [86-90]. The unspecific mucosal defense is mediated by physical and 
chemical barriers. The physical barrier is composed by the mucosal epithelium which 
prevents penetration of pathogens into the host. The epithelial cells can form a single 
layer or multilayers and their integrity defines the access of antigens to dendritic cells, 
crucial for initiating a pathogen-specific adaptive immune response [91]. Mucociliary 
clearance in the airways of the host is one of the most important non-specific 
mechanisms against pathogen colonization. The respiratory mucosa is composed of a 
mucus layer and special ciliary epithelial cells that provide the clearance of the 
pathogens from the mucosal surface by constant mechanical movements. Mucosal 
chemical barriers are composed of mucins, inhibitors of pathogen growth and anti-
microbial peptides, such as defensins, which are secreted by epithelial cells [92].  
Antigen-specific secretory IgA is the central mediator of the pathogen-specific mucosal 
immune response and is produced at the basolateral side of the mucosal epithelium 
[51]. B cells become activated by antigen recognition followed by interaction with Th2 
cells and mature under the influence of local cytokines, such as APRIL (a proliferation-
inducing ligand) and BAFF (B cell-activating factor) originating from dendritic cells [47]. 
They undergo a class switch driven towards the IgA isotype and become plasma cells 
that secrete dimeric or polymeric IgA [93]. IgA is taken up at the basolateral side of the 
epithelium and transported across epithelial cells via transcytosis to the mucosal surface 
where it neutralizes foreign antigens [94]. 
1.2.2 Evoking immune responses by mucosal vaccines 
Antigen-specific secretory IgA prevents the colonization of mucosal surfaces by 
pathogens and can be evoked by vaccination [95]. Mucosal vaccines can be 
administered orally or applied directly on the mucosal surface of the respiratory and 
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urogenital tracts as liquids or aerosols. The existence of a mucosal network allows the 
stimulation of mucosal responses at distant mucosal territories after vaccination at a 
particular mucosal site [96]. However, there is a certain degree of compartmentalization 
in the mucosal immune system and it should be considered when defining the 
vaccination route to evoke immune responses at specific mucosal areas [97, 98]. 
Mucosal vaccines delivered by the same route as their target pathogen evoke immune 
responses that mimic those observed after natural infections. For example, the live 
attenuated vaccine against the polio virus is administered orally and this virus enters the 
host via the intestinal tract, where the primary infection takes place [99]. On the other 
hand, vaccine candidates against air-borne pathogens, such as influenza virus [100], 
respiratory syncytial virus [101] and nontypeable Haemophilus influenzae [102] are 
administered by the intranasal (i.n.) route and promote stronger responses than those 
administered via the oral route.  
Although there are clear advantages of evoking a mucosal adaptive immune response 
via vaccination, the efficacy of the administered vaccine depends on the ability to deliver 
the antigen to APCs across the mucosa. This is hampered by the natural barrier 
functions of the mucosa, such as: i) physical clearance of antigens via ciliary epithelial 
cells ii) chemical degradation of antigens due to enzymes and low pH and iii) limited 
transport through mucosal barrier [103, 104]. Therefore, to improve the efficacy of 
mucosal vaccines it is necessary to develop formulations capable of the delivery of 
antigens to APCs by crossing the epithelial layer. From this point of view, the 
administration of antigens through the nasal mucosa seems to be more attractive than 
the oral route, where the higher abundance of enzymes increases the risk of 
degradation of the administered vaccine components. Furthermore, i.n. applied vaccine 
formulations can take advantage of the nose-associated lymphoid tissues (NALT) that 
would provide compact immune responsive cell populations in close proximity to the site 
of administration [105]. 
1.2.3 Evoking adaptive immune responses via the NALT  
As shown by Wu et al., the central site of mucosal immune response induction upon i.n. 
immunization in rodents is the NALT, an equivalent of the Waldeyer´s ring in humans 
[106]. The NALT is composed of lymphoid tissue enveloped in an epithelial layer which 
contains microfold (M) cells [107]. The epithelium prevents dendritic cells to directly 
access the nasal cavity and sample for antigens. Instead, the M cells are enrolled in the  
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delivery of the antigens from the apical to the basolateral surface of the mucosal tissue. 
There, dendritic cells take up and deliver antigens to T or B cells to stimulate them 
locally or migrate to draining lymph nodes to initiate their proliferation and migration to 
distal mucosal tissues [86] (figure 4).  
Figure 4: The initiation of an immune response at the nasal mucosa. Antigens are taken up 
by M cells and are transported via transcytosis to dendritic cells located at the basolateral site of 
the mucosal tissue. Dendritic cells initiate adaptive responses via presentation of antigens to 
resident T or B cells or migrate from the mucosal site to draining lymph nodes (modified from 
[108]). 
1.2.4 Formulations of mucosal vaccines 
Most of the antigens in mucosal vaccines nowadays are delivered as live attenuated 
organisms (e.g. polio, cholera, influenza, typhoid vaccine) [109, 110]. Although live-
attenuated vaccines have proven to induce effective immune responses, their limitations 
become evident when specific groups of patients do not respond or show unexpected 
adverse effects. Mostly, it is not known which specific vaccine component has to be 
modified to solve these problems. For example, a live attenuated vaccine against 
rotavirus gastroenteritis administered via the oral route was withdrawn from the market 
due to cases of intussusception in patients [111], but the exact cause has never been 
identified. Notably, the empirical formulation of vaccines does not allow benefiting from 
knowledge gained from failed vaccine clinical trials, which makes vaccine development 
costly in the long term. Furthermore, the attenuation of pathogens sometimes does not 
exclude risks, such as back reversion to virulence. Knowing the exact composition of 
vaccines would allow controlling the risks of applying compounds with toxic, allergenic or 
autoimmune potential. In addition, a defined vaccine composition would help to ensure 
that the evoked immune profile is suitable to fight multiple strains by incorporation of  
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antigens specific for multiple strains of a pathogen [112]. To this end, recombinant 
attenuated pathogens, DNA constructs, pathogen subunits or synthetic peptides can be 
used as antigens. Since their immunogenicity is usually weak, adjuvants can be 
incorporated in such formulations. Adjuvants are compounds that enhance and 
modulate adaptive immune responses to co-administered antigens [113].  
1.2.5 Mucosal adjuvants  
Cholera toxin and heat-labile Escherichia coli enterotoxin are well studied mucosal 
adjuvants in animal experimental systems. However, their application in humans 
requires the attenuation of their toxicity [114-116], as became apparent in the case of 
the virosomal-subunit influenza vaccine where E. coli heat-labile toxin was used as a 
mucosal adjuvant. This vaccine was withdrawn from clinical use due to the correlation of 
cases of Bell´s palsy in patients with vaccine administration [117].  
Most of the adjuvanted vaccine formulations which are commercially available today are 
administered parenterally and contain alum-based adjuvants. A list of licensed adjuvants 
is given in table 1. It has been suggested that alum-induced activation of the Th2 
response suppresses Th1 development [118], finally evoking a dominant humoral 
immune response to vaccination [119, 120]. Interestingly, a recent report described the 
use of alum in mucosal vaccine where it enhanced the Th1 and antibody responses, 
when compared to the response profile evoked by a formulation containing cholera toxin 
as adjuvant [121]. Although alum-based adjuvants are the most used, there are several 
problems related to their stability, costly shipping and long term storage [122]. To make 
vaccines available that evoke effective Th1 responses and can be distributed at low 
costs, alternative adjuvants would be needed. Furthermore, it would be desirable that 
the molecular mechanisms underlying the immune modulatory potency of adjuvants are 
well understood to meet the following requirements for the development of novel 
vaccines:  
‒ Improved efficacy accomplished by combining compatible antigens, adjuvants 
and the optimal route of administration 
‒ Options to rationally design formulations eliciting predictable immune responses, 
which provide effective protection against the target pathogen 
‒ Better prediction of risk of potential undesired effects, based on the knowledge 
about adjuvant-triggered pathways that are not directly involved in evoking the 
immune response 
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Taken together, it is necessary to perform preclinical studies to identify immune 
modulators and characterize their patterns of immune response elicitation and safety 
profiles to develop safe vaccine formulations with the efficacy of live attenuated 
vaccines. 
Table 1: Adjuvants licensed for use in human vaccines. (adapted from [123]) 
Adjuvant name  
(year licensed) 
Adjuvant class Components 
Vaccines 
(diseases) 
Alum* 
 (1924) 
Mineral salts 
Aluminium phosphate or 
aluminium hydroxide 
Various 
MF59  
(Novartis; 1997) 
Oil-in-water 
emulsion 
Squalene, polysorbate 
(Tween 80; ICI Americas), 
sorbitan trioleate (Span 
85; Croda International) 
Fluad (seasonal 
influenza), Focetria 
(pandemic influenza), 
Aflunov (pre-pandemic 
influenza) 
ASO3 
(GSK; 2009) 
Oil-in-water 
emulsion 
Squalene, Tween 80,  
α-tocopherol 
Pandremix (pandemic 
influenza), Prepandrix 
(pre-pandemic 
influenza) 
Virosomes  
(Berna Biotech; 
2000) 
Liposomes Lipids, hemagglutinin 
Inflexal (seasonal 
influenza), Epaxal 
(hepatitis A) 
ASO4*  
(GSK; 2005) 
Alum-absorbed 
TLR 4 agonist 
Aluminium hydroxide , 
MPL 
Fendrix (Hepatitis B), 
Cervarix (human 
papilloma virus) 
* The only adjuvants licensed in the United States.  
1.3 Bacterial cyclic di-nucleotides 
The cyclic di-nucleotides (CDNs) bis-(3´,5´)-cyclic dimeric guanosine monophosphate 
(c-di-GMP), bis-(3´,5´)-cyclic dimeric adenosine monophosphate (c-di-AMP) and (3',5'-
3',5')-cyclic (adenosine monophosphate-guanosine monophosphate) (cGAMP) are well 
known bacterial second messengers, involved in processes such as biofilm formation, 
regulation of virulence and motility [124-126] (figure 5). The cGAMP is the latest 
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discovered CDN [126] and represents the prokaryotic isoform of the already mentioned 
(2’,5’)-cGAMP (section 1.1.1.2). CDNs have been described as important factors of 
pathogens to colonize hosts. For example, c-di-GMP can decrease the pathogenicity of 
Listeria monocytogenes, Mycobacterium tuberculosis and Vibrio cholerae [127-129]. 
Overproduction of c-di-AMP seems to be involved in the regulation of L. monocytogenes 
[130, 131] and M. tuberculosis virulence [132]. cGAMP is known to increase host 
colonization by V. cholerae [126].  
 
Figure 5: Chemical structure of bacterial cyclic di-nucleotides. (adapted from [133]) 
 
As many PAMPs, CDNs induce the production of IFN-β via Sting [134-137]. However, 
cGAMP cannot be considered as a classical PAMP since its isoform is present in 
mammalian cells. The interest in CDNs for the application in mucosal vaccines has been 
growing due to the proven ability of c-di-GMP and c-di-AMP to enhance balanced 
humoral and cellular responses to the model antigen ovalbumin (OVA) in murine models 
[138, 139]. Therefore, it would be interesting to test if cGAMP shows immune 
modulatory potential and if it is equivalent to the already described immune modulatory 
potential of the candidate adjuvant c-di-AMP. This question will be addressed in this 
thesis [140].  
Although a series of adjuvant effects of CDNs have been well described, the molecular 
basis of their activity on the host immune system still remains to be elucidated. Current 
knowledge does not allow extrapolation of conclusions based on findings with one of the 
CDNs to all of them. For example, X-ray crystal structures of direct binding to Sting have 
been resolved for c-di-GMP [141, 142], cGAMP and (2´,5´)-cGAMP [36], whereas the 
attempts of crystalizing c-di-AMP bound to Sting have been so far unsuccessful. This 
leaves the option of alternative sensor(s) of c-di-AMP that interact with Sting to induce 
IFN-β production. For instance, Parvatyar et al. [137] described that the cytosolic dsDNA  
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sensor DDX41 can act as a direct sensor of c-di-GMP and c-di-AMP and pointed to the  
role of Sting as an adaptor in triggering the production of IFN-β. In addition, it cannot be 
excluded that different CDNs trigger signals from different domains of Sting, activating 
cascades that differentially contribute to their adjuvanticity. Having in mind that CDNs 
induce the production of IFN-β, it would be interesting to see if type I IFN pathways play 
a role in their adjuvanticity. Although the induction of type I IFNs early upon virus 
encounter is essential for the host defense, in bacterial infections the activity of type I 
IFNs depends on the invading pathogen and is not always beneficial to defend the host. 
For example, type I IFNs have been described as an important factor for fighting several 
gram positive bacteria [143-145], but its production upon L. monocytogenes infection 
seems to be the pathogen´s strategy to down-regulate the long term immune response 
of the host [146]. These observations point to the activity of type I IFNs as an important 
factor in development of immunity against specific pathogens and could be also 
assumed to be relevant for immune responses evoked by vaccination. The biological 
effects of type I IFNs are mediated by their receptor IFNAR. Blaauboer et al. reported 
that Sting, but not IFNAR plays a crucial role in enhancing the responses in 
immunization studies using c-di-GMP as an adjuvant [147]. Therefore, it would be 
interesting to investigate if the c-di-AMP and cGAMP-triggered type I IFN pathways play 
a role in their adjuvanticity and if the outcome of this study would differ from the findings 
published for c-di-GMP. 
1.4 The aims of this thesis and experimental strategies  
The thesis presented here was designed to contribute to the characterization of CDNs 
as candidate mucosal adjuvants. It aims at the investigation of the immune response 
profiles associated with the application of CDNs in vivo and the in vitro identification of 
cellular activation profiles that could be used as surrogate markers to predict immune 
responses evoked by CDNs. These activation markers can be further used as readouts 
for biochemical studies elucidating the pathways triggered by CDNs and their actual 
relevance for the adjuvanticity of CDNs can be addressed. To fulfill these overall aims, 
the experimental activities are focused on four specific areas.  
First, the characterization of the recently discovered cGAMP in terms of its adjuvant 
potential should be performed by carrying out immunization studies in which the model 
antigen OVA should be administered alone or together with cGAMP by i.n. route to mice 
according to a three dose-immunization schedule. Two weeks after the third 
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immunization indicators of adaptive immune responses should be measured in serum 
and tissue samples from the immunized animals. Antigen-specific humoral responses 
should be determined by enzyme-linked immunosorbent assay (ELISA). To assess 
cellular responses, spleen cells should be re-stimulated with OVA. The proliferation of 
re-stimulated spleen cells should be measured by 3H-thymidine incorporation assays. 
The cytokine production of re-stimulated spleen cells, indicative for Th1, Th2 or Th17 
responses should be measured by enzyme-linked immunospot assays (ELISPOT) or 
flow cytometry. Then, the OVA-specific immune responses obtained in groups of 
animals immunized with the antigen alone or co-administered with cGAMP should be 
compared to assess the potential of GAMP as adjuvant. 
Second, if cGAMP shows adjuvant properties, the efficacy of cGAMP and c-di-AMP to 
enhance adaptive immune response should be compared to explore their potential at 
inducing differential immune response profiles. To this end, immunization studies using 
experimental groups immunized with the model antigen OVA alone or co-administered 
with cGAMP or c-di-AMP should be measured as described above and resulting evoked 
immune responses should be compared side-by-side.   
Third, if any differences at the effector level of the c-di-AMP and cGAMP activity are 
found, in vitro systems should be established to derive hypotheses explaining their 
differential activities. To this end, bone marrow-derived dendritic cells (BMDCs) should 
be used as a model system for CDN-responsive innate immune cells, and the surface 
expression of the activation markers MHC class II, CD86 and CD80, together with the 
production of key cytokines (e.g. type I IFNs, IL-6, IL-12/IL-23p40) should be measured 
as indicators of CDN-induced activation. To this end, flow cytometry or ELISA should be 
applied. 
Fourth, to address the relevance of type I IFN induction and signaling pathways for the 
adjuvanticity of c-di-AMP and cGAMP, their efficacy in animals lacking functional 
components of these pathways should be tested. The lack of Sting impairs the CDN-
triggered production of type I IFNs. The lack of functional IFNAR impairs the signaling 
mediating the biological activities of type I IFNs, such as up-regulation of ISGs. 
Therefore, to test if any of these type I IFN pathways are involved in mediating the 
adjuvanticity of c-di-AMP or cGAMP, immunization studies using wild type (wt) animals 
and mice lacking functional Sting or IFNAR should be performed as described above. 
OVA-specific immune responses should be compared in animals immunized with OVA 
alone or OVA co-administered with CDN. This should allow assessing if the CDN- 
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mediated enhancement of OVA-specific immune response observed in wt animals is  
impaired in any of the animals with a dysfunctional type I IFN pathway, thereby enabling 
to draw conclusions on the role played by a particular molecule on the adjuvanticity of a 
specific CDN. 
 Materials and methods 
 
 30          Identification of molecular mechanisms mediating the adjuvanticity of cyclic di-nucleotides 
2 MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Technical equipment 
Table 2: Technical equipment  
Equipment Manufacturer/ country 
Cell counter, Z2 Coulter counter Beckman Coulter, Germany 
Cell culture dishes Greiner, Germany 
Cell harvester Inotech, Switzerland 
Centrifuge, 5417 R Eppendorf, Germany 
Centrifuge, Multifuge 3 S-R Thermo Scientific, Germany 
ChemiDocTM MP Imaging System Bio-Rad, Germany 
CTL ELISPOT reader  Cellular Technology, Ltd., Germany  
Electrical source for agarose electrophoresis Pharmacia LKB, Sweden 
ELISA washer  Biotek, Germany 
Falcon tubes Greiner, Germany 
Flow cytometry measurement tubes 1.2 ml MP Biomedicals, France 
Flow cytometry measurement tubes 5 ml BD Bioscience, USA 
Heraeus Multifuge x3R Thermo scientific, Germany 
High binding ELISA plates Greiner, Germany  
Incubator, Heracell 240i Thermo Scientific, Germany 
LSR-II SORP BD Biosciences, USA 
MultiScreen HTS filter plates  Milipore, Germany 
Nitrocellulose membrane Bio-Rad, Germany 
pH-meter Hannah Instruments, Germany 
96F plates  TPP, Switzerland 
PTC-100
TM
 Programmable Thermal controller MJ Research, Inc., USA 
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Precision 2000 automated microplate pipetting 
system 
Biotek, Germany 
Serological pipets Roth, Germany 
Sterile hood, LaminAir Heraeus, Germany 
Synergy 2 Multi-Mode Microplate Reader  Biotek, Germany  
Semi-dry blotter Biometra, Germany 
T Filtermat A filters  PerkinElmer, USA 
Thermomixer compact Eppendorf, Germany 
Tumbling table Analytik Jena, Germany 
γ scintillation counter (1450 Microbeta Trilux) Wallach Sverige, Sweden 
Water bath  Köttermann, Germany 
2.1.2 Chemical substances 
Table 3: Chemical substances 
Chemical substance Manufacturer 
2,2´-azino-bis (3-ethylbenzthiazoline-6 sulfonic acid) 
diammonium salt (ABTS) 
Sigma-Aldrich, Germany 
3-amino-9-ethyl-carbazole (AEC) substrate kit BD Pharmingen, USA 
Amersham enhanced chemiluminescence (ECL) 
Prime Western Blotting Detection Reagent 
GE-Healthcare, Germany 
Ampuwa Serumwerk, Germany 
Ammonium persulfate (APS)  Bio-Rad, Germany 
Avidin-horseradish peroxidase (HRP) BD Pharmingen, USA 
β-mercaptoethanol Merck, Germany  
Bromophenolblue Sigma-Aldrich, Germany 
Bovine serum albumin (BSA) Carl Roth, Germany 
Calyculin A Cell Signaling, Netherlands 
Citric acid Sigma-Aldrich, Germany 
c-di-AMP  Biolog, Germany 
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c-GAMP (3´,3´) Biolog, Germany 
Dimethyl sulfoxide (DMSO) Applichem, Germany 
Ethanol 100% Roth, Germany  
Ethylenediaminetetraacetic acid (EDTA) Roth, Germany 
Fetal calf serum (FCS) Biochrom, Germany 
GeneRuler DNA ladder mix  Thermo Scientific, Germany 
Gentamicine Gibco, UK 
L-Glutamine Gibco, UK 
Glycerol Sigma-Aldrich, Germany 
Granulocyte-macrophage colony stimulating factor 
(GM-CSF) 
eBioscience, Germany 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) 
Serva, Germany 
Hydrogen peroxide (H2O2)  Sigma-Aldrich, Germany 
3
H-thymidine PerkinElmer, USA 
Isotone II Coulter-Beckman, USA 
Kaleidoscope Prestained standard Bio-Rad, Germany 
Lipopolysaccharide (LPS) Sigma-Aldrich, Germany 
Magnesium chloride (MgCl2) Carl-Roth, Germany 
Methanol J. T. Baker, Germany 
2-Mercaptoethanol (50 mM)  Gibco, UK 
Midori green advanced green DNA stain Nippon Generics, Germany 
Milk powder Roth, Germany 
My TaqTMHS Redmix 2x Bioline, Germany 
NEEO Ultra Quality Roti Agarose Roth, Germany 
OVA protein EndoGrade, Hyglos, Germany 
Paraformaldehyde (PFA) Riedl-de-Hän, Germany 
Phenylmethanesulfonyl fluoride (PMSF)  Sigma-Aldrich, Germany 
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Ponceau S Sigma, Germany  
Penicillin/streptomycin (100x concentrated, 10000 IU 
penicillin, 10000 μg/ml streptomycin) 
Gibco, UK 
Potassium bicarbonate (KHCO3) Sigma, Germany  
Potassium dihydrogen phosphate (KH2PO4) Merck, Germany 
Precision Plus Protein Kaleidoscope   Bio-Rad, Germany 
Protease Inhibitor Cocktail Sigma-Aldrich, Germany 
Proteinase K Bioline, Germany 
Rotiphorese gel 30 (30% acrylamide, 0.8% 
bisacrylamide) 
Carl-Roth, Germany 
RPMI 1640 Gibco, UK 
Saponin  Sigma-Aldrich, Germany 
Sodium dodecyl sulfate (SDS) Sigma-Aldrich, Germany 
Sodium hydrogen carbonate (NaHCO3)  Merck, Germany 
Sodium chloride (NaCl) Carl-Roth, Germany 
Streptavidin-HRP Sigma-Aldrich, Germany 
Streptavidin-HRP, BD ELISPOT BD Bioscience, USA 
Tetramethylethylenediamine (TEMED)  Carl-Roth, Germany 
Tween 20  Carl-Roth, Germany 
 
2.1.3 Antibodies 
Table 4: Antibodies used in flow cytometry analyses 
Antibody conjugated with a 
fluorochrome* 
Clone Dilution Catalog 
number 
Manufacturer 
Rat, anti-mouse CD16/CD32  
(Fc-block) 
93 1:1000 101319 
Biolegend, 
Germany 
Rat, anti-mouse CD11b 
(eFluor450-conjugated) 
M1/70 1:400 48-0112-82 
eBioscience, 
Germany 
Hamster, anti-mouse CD11c 
(Pe-Cy7-conjugated) 
N418 1:800 117317 
BD Pharmingen, 
USA 
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Mouse, anti-mouse I-A
b
 MCH-II 
(FITC-conjugated) 
AF6-120.1 1:100 553551 
BD Pharmingen, 
USA 
Rat, anti-mouse CD86  
(PE-conjugated) 
GL1 1:500 553692 
BD Pharmingen, 
USA 
Hamster, anti-mouse CD80 
(APC-conjugated) 
16-10A1 1:1200 17-0801-82 
eBioscience, 
Germany 
Rat, anti-mouse CD3  
(FITC-conjugated) 
145-2c11 1:300 553062 
BD Pharmingen, 
USA 
Rat, anti-mouse CD4  
(PE-Cy7-conjugated) 
RM4-5 1:1000 25-0042-82 
eBioscience, 
Germany 
Rat, anti-mouse CD8  
(APC-conjugated) 
53-6.7 1:500 17-0081-81 
eBioscience, 
Germany 
Rat, anti-mouse IL-17  
(V450-conjugated) 
TC11-1 
8H10 
1:200 560522 
BD Bioscience, 
USA 
Rat, anti-mouse TNF-α  
(PerCP-eF710-conjugated) 
MPG-XT22 1:200 46-7321-82 
eBioscience, 
Germany 
Rat, anti-mouse IL-6  
(PE-conjugated) 
MP5-20F3 1 :200 12-7061-71 
eBioscience, 
Germany 
Rat, anti-mouse IL-12/IL-23p40 
(Alexa647-conjugated) 
C17.8 1:400 51-7123-80 
eBioscience, 
Germany 
 
*phycoerythrin-cyanin 7 (Pe-Cy7), fluorescein-isothiocyanate (FITC), phycoerythrin (PE), 
allophycocyanin (APC), peridinin-chlorophyll-protein complex (PerCP)  
 
Table 5: Antibodies used in Western blot 
Antibody Clone Dilution Catalog number Manufacturer 
Primary 
Rabbit, anti-mouse Sting -- 1:2000 
3337S Cell Signaling, 
Germany 
Secondary  
Goat, anti-rabbit-HRP -- 1:20000 111-035-144 Jackson 
Immunoresearch, 
USA 
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Table 6: Antibodies used in ELISA 
Antibody Dilution Catalog number Manufacturer 
Elisa capture antibodies   
Goat, anti-mouse IgA 1:500 M-8769 Sigma-Aldrich, Germany  
Elisa biotinylated detection antibodies   
Goat, anti-mouse IgA 1:5000 1040-08 Southern Biotech, USA 
Goat, anti-mouse IgG  1:5000 B7022-1ml Sigma-Aldrich, Germany 
Goat, anti-mouse Ig1  1:5000 1072-08 Southern Biotech, USA 
Goat, anti-mouse IgG2c  1:5000 1079-08 Southern Biotech, USA 
 
Table 7: Antibodies used in ELISPOT 
Antibody Dilution Catalog number Manufacturer 
ELISPOT capture antibodies 
Anti-mouse IFN-γ 1:200 51-2525KZ BD Bioscience, USA 
Anti-mouse IL-2 1:200 51-1816KZ BD Bioscience, USA 
Anti-mouse IL-4 1:200 51-1819KZ BD Bioscience, USA 
Anti-mouse IL-17A 1:250 16-7175-68 eBioscience, USA 
ELISPOT biotinylated detection antibodies 
Anti-mouse IFN-γ  1:250 51-1818KZ BD Bioscience, USA 
Anti-mouse IL-2 1:250 51-1817KZ BD Bioscience, USA 
Anti-mouse IL-4 1:250 51-1804KZ BD Bioscience, USA 
Anti-mouse/rat IL-17A 1:250 13-7177-68C eBioscience, USA 
2.1.4 Solutions and buffers 
Table 8: Solutions and buffers 
Solution/ buffer Composition 
Ammonium chloride-potassium 
(ACK) lysis buffer 
0.1 mM EDTA, 1mM KHCO3, 155 mM NH4Cl, pH 7.3 
Antibody storage solution 2% (w/v) BSA, 0.02% (w/v) NaN3 in TBS 
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Blotting buffer 24.8 mM Tris, 19.2 mM glycine, 2% (v/v) methanol 
Cell lysis buffer for sodium 
dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-
PAGE)  
20 mM HEPES, 50 mM KCl, 2 mM MgCl2, 1% (v/v) Triton 
X-100, 100 nM calyculin A, 0.03% (v/v) protease inhibitor 
cocktail, 1 mM PMSF 
Flow cytometry 
permeabilization buffer 
0.5% (w/v) BSA, 0.5% saponin in PBS  
Flow cytometry fixation buffer 2% (v/v) PFA in  PBS 
ELISA coating buffer 0.05 M carbonate buffer, pH 8.2 
ELISA blocking buffer  3% (w/v) BSA in PBS 
ELISA washing buffer  0.1% (v/v) Tween20 in PBS 
ELISA sample dilution buffer  3% (w/v) BSA in PBS 
ELISA antibody dilution buffer 1% (w/v)  BSA/0.1% (v/v) Tween 20 in PBS 
ELISA substrate solution 0.5 mM ABTS, 0.03% H2O2 in 0.1 M citrate-phosphate 
buffer, pH 4.35 
Lysis buffer for tissue biopsies 0.45% nonidet P40, 0.45% tween 20, 0.1% gelatine, 50 mM 
KCl, 1.5 mM MgCl2, 10 mM Tris HCl, pH 8.5 
Proteinase K freshly added: 2.76 U per 500 μl of lysis buffer 
4x Loading buffer  
(Protein Solubilization buffer) 
40% (v/v) glycerol, 240 mM Tris HCl pH 6.8, 8% (w/v) SDS, 
0.08% (w/v) bromophenol blue (3',3",5',5"-
tetrabromophenolsulfonphthalein), 4% (v/v) 2-
mercaptoethanol 
Nasal wash buffer 5% FCS (v/v) in PBS 
Phosphate-buffered saline 
(PBS)  
0.27 mM KCl, 0.18 mM KH2PO4, 13.7 mM NaCl, 1mM 
Na2HPO4, pH 7.4 
Tris-acetate-EDTA (TAE) 
buffer  
0.04 M Tris, 1 mM EDTA, 0.04 M acetic acid, pH 8.0 
Tris-buffered saline (TBS) 20 mM Tris, 0.5 M NaCl, pH 7.4 
Tris-buffered saline Tween 20 
(TBS-T) 
20 mM Tris, 0.5M NaCl, 0.05% (v/v) Tween 20, pH 7.4 
SDS-Running buffer 24.8 mM Tris, 19.2 mM glycine, 0.1% (w/v) SDS 
Stacking gel buffer  0.5 M Tris, pH 6.8 
Separation gel buffer  1.5 M Tris, pH 8.8 
Western blot blocking solution 5% (v/v) milk in TBS 
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2.1.5 Cells 
Table 9: Cell line used in experiments  
2.1.6 Cell culture media 
Table 10: Cell culture media 
Media Supplements 
RPMI 1640 complete 10% v/v FCS heat inactivated (h.i.), 100 U/ml penicillin, 50 
μg/ml streptomycin, 2-mercaptoethanol 50 μM, 2 mM L-
glutamine 
RPMI 1640 for BMDCs 10% v/v FCS heat inactivated, 100 U/ml penicillin, 50 μg/ml 
streptomycin, 2-mercaptoethanol 50 μM, 2 mM L-glutamine, 
50 μg/ml gentamicin 
HEK-Blue growth medium  DMEM high glucose (4.5 g/l), 10% v/v FCS heat 
inactivated, 100 U/ml penicillin, 50 μg/ml streptomycin, 1 x 
normocin 
HEK-Blue selection medium HEK blue growth medium supplemented with HEK-Blue 
Selection 
HEK-Blue detection medium 1 pouch of HEK-blue detection in 50 ml endotoxin-free H2O, 
sterile filtered through 0.2 μm pore membrane 
2.1.7 Mice 
Table 11: Mice used in experiments 
Mouse Description Provider 
wt  C57/BL6  Harlan, Germany  
IFNAR1
-/-
 Animals lacking functional 
IFNAR1, developed on 
C57/BL6 background [148]  
Kindly provided by Prof. Dr. 
U. Kalinke (Twincore, 
Hannover, Germany) 
Sting
Gt/Gt
 Animals lacking functional 
Sting, Sting
Gt/Gt
 (Sting 
goldenticket, C57BL/6J-
Tmem173gt/J)  
[135] 
Jackson Laboratory, USA 
Cell type Description 
Human embryonic kidney 
(HEK)-Blue mTLR4 
Cell line purchased from InvivoGen, stably transfected to 
express murine TLR4 at high levels and alkaline 
phosphatase reporter gene under the control of a promoter 
inducible by transcription factor NF-kB  
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2.1.8 Primers for genotyping IFNAR-/- mice 
Table 12: Primers used in PCR for genotyping (Provided by Eurofins) 
Primer Sequence 
1 5´CCA AGC GAA ACA TCG CAT CG3´ 
2 5´GTT CCC TTC CTC TGC TCT G3´ 
3 5´ACA AAA GAC GAG GCG AAG TG3´ 
2.1.9 Kits used for cytokine detection and live/dead cell stain  
Table 13: ELISA, ELISPOT and live/dead cell stain kits  
 
2.2 Methods 
2.2.1 LPS detection using the HEK-blueTM LPS detection Kit  
Stock solutions of the components used in immunization experiments were tested for 
the presence of LPS contaminations higher than 1.6 ng/ml using the HEK-blueTM LPS 
detection Kit according to the manufacturer´s instructions. The detection limit of this 
method for E. coli K12 LPS is 0.3 ng/ml. Briefly, the HEK-Blue-4 cells were cultured in 
HEK-Blue growth medium at 37°C, 5% CO2 in a humidified atmosphere until 50–80% 
confluence was reached. Then, the cells were detached using trypsin, transferred into  
HEK-Blue selection medium and passaged twice a week. When the confluence of 60–
80% was reached, the cells were detached using trypsin and diluted in pre-warmed 
HEK-Blue detection medium to a concentration of 1 x 105 cells/ml. To a 96-well sterile 
flat-bottomed cell culture plate were added 20 μl/well of each sample to be tested (c-di-
AMP, cGAMP and OVA stock solutions used in immunization formulations), and 20 
μl/well of endotoxin-free water as a negative control. As a positive control, 20 μl/ well of 
Kit Manufacturer 
IFN-β Biolegend Max ELISA kit Biolegend, Germany 
VeriKine
TM
 Mouse Interferon Alpha ELISA kit PBL, USA 
Mouse IFN-γ, IL-2, IL-4 or IL-17 ELISPOT pair kit BD Biosciences, USA 
Live/Dead® Fixable dead cell stain Kit Life technologies, Germany 
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E. coli K12 LPS at a concentration of 1.625, 3.125, 6.25, 12.5, 25, 50 and 100 ng/ml 
were added. Then, 200 μl/ well of cell suspension was added and the plate was 
incubated for 24 h at 37°C, 5% CO2. HEK-Blue-4 cells express at high levels stably 
transfected murine LPS receptor TLR4, which makes them very sensitive to LPS. In 
addition, they are stably transfected to express an alkaline phosphatase reporter gene, 
which is controlled by NF-κB. In presence of LPS, the signaling axis from TLR4 via NF-
κB induces expression of alkaline phosphatase, which is secreted and reacts with the 
substrate HEK-Blue detection in the growth medium, giving a blue colored product. 
Spectrophotometric measurement of the absorbance at 630 nm 24 h upon the treatment 
allows semi-quantification of alkaline phosphatase activity, which is correlated to up-
regulation of its expression due to presence of LPS. The minimal dose of LPS potentially 
inducing innate immune cell priming in vivo is 0.1 ng [149]. To cause innate immune cell 
priming by LPS contamination in the immunization experimental system described in 
2.2.7, LPS would be required in a minimal concentration of 33 ng/ml in OVA or 20 ng/ml 
in c-di-AMP and cGAMP stock solutions. Based on the comparison of the absorbance 
values of the samples with cells incubated with CDN or OVA stock solution with to the 
absorbance values of the blank and LPS in defined concentrations, presence of LPS in 
immunization stock solutions in minimal concentrations potentially causing immune 
stimulatory effects in vivo was estimated. 
2.2.2  IFNAR-/- genotyping by PCR 
DNA samples obtained from supernatants of lysed tail biopsies of mice were analyzed 
by polymerase chain reaction (PCR). Briefly, the biopsies were lysed in tail lysis buffer 
containing proteinase K, overnight at 56°C under constant shaking at 800 rpm. 
Proteinase K is a serine protease that is used here to degrade native as well as 
denatured proteins. Proteinase K was deactivated by exposing the samples to 96°C for 
10 min after the lysis procedure. Then, the samples were cooled down and 2 μl of 
sample suspensions were used for a PCR reaction of a total volume 25 μl. A single 
reaction contained 12.5 μl of DNA Pol Redmix, 1μl DMSO, 2μl H2O and 2.5 μl of each of 
the primers given in table 12, at the final concentration of 10 μM. The protocol of PCR 
cycles is given in figure 6. 
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Figure 6: PCR temperature cycles for IFNAR genotyping. Tissue lysate samples were used 
for PCR performed with the temperature cycles shown.  
 
The PCR products were analyzed by agarose gel electrophoresis. To this end, 2% (w/v) 
agarose gels were prepared in TAE buffer containing Midori Green (60 μl/l), a nucleic 
acid dye which, upon exposure to ultraviolet (UV) light, emits green fluorescence when 
bound to DNA and therefore allows the visualization of DNA bands. PCR samples were 
loaded onto the gel and the GeneRuler LadderMix was used as a DNA fragment size 
standard. The gel electrophoresis was performed for 1 h at 120 V and the DNA was 
visualized by exposing the gels to UV light of 270 nm wavelength and the detection of 
emitted light at wavelength 530 nm using the GelDocXRS system. 
2.2.3 Sting detection by Western blot 
2.2.3.1 Cell lysis 
BMDCs (3x105) from wt, IFNAR-/- or StingGt/Gt mice were lysed in 10 µl lysis buffer for 
Western blot. The lysis was performed on ice for 10 min and the samples were 
thoroughly stirred after 5 min. Then, 4 μl of 4 x concentrated loading buffer and β-
mercaptoethanol at final concentration 4% (v/v) were added. The lysates were boiled for 
7 min at 96°C and spun down prior to SDS-PAGE.  
2.2.3.2 SDS-PAGE 
The SDS-PAGE is a method for the separation of proteins based on their molecular 
weight. SDS-denatured polypeptides carry amounts of the negatively charged anionic  
detergent SDS proportional to their molecular weight. They move in an electric field 
towards the positively-charged electrode (anode). Differential electrophoretic mobility of 
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polypeptides in PAGE is defined by the pore size in the gel that allows faster movement 
of smaller polypeptides, resulting in their separation in the gel and highly depends on the 
concentration of acrylamide. Polymerization of acrylamide and bisacrylamide monomers 
requires presence of free radicals in a polymerizing gel mixture, which is ensured by 
adding APS and TEMED. APS spontaneously decomposes to form free radicals and 
therefore initiates the polymerization. TEMED is a free radical stabilizer and is included 
to promote the polymerization. The gel was prepared in two phases: stacking (4.2% 
acrylamide) and separation phase (10% acrylamide). The gel running was done in a gel 
chamber Mini-PROTEAN II, First, the samples were run through the stacking gel at 
15 mA for approximately 45 min.  This step was followed by running the samples in the 
separation gel, where was applied constant current of 20 mA for approximately another 
1 h. When the front dye bromophenolblue reached the end of the separation gel, the 
SDS-PAGE was stopped and the Western blot was performed in order to detect specific 
proteins on a nitrocellulose membrane. 
2.2.3.3 Western blot 
First, the proteins from the gel were blotted on a nitrocellulose membrane. The 
procedure was done in a semi-dry manner, where Whatman paper and a nitrocellulose 
membrane were first equilibrated in blotting buffer. Then, a sandwich of 3 layers of 
Whatman paper, the nitrocellulose membrane, the polyacrylamide gel and another 3 
layers of Whatman paper were placed on the blotter with paying attention that the 
membrane is positioned between the SDS gel and the positive electrode, towards which 
the proteins will move. The protein transfer from the SDS gel to the nitrocellulose 
membrane was performed for 1 h at constant current of 45 mA. Then the Ponceau S 
staining of the proteins transferred to nitrocellulose membrane was performed to verify if 
approximately equal amount of proteins was loaded per lane. 
Next, the unspecific binding sites on the membrane were blocked by incubation in 5% 
TBS-T-milk, overnight at 4°C with constant shaking. Then, the membrane was washed 
in 4 cycles of 10 min shaking in TBS-T and incubated with specific antibody diluted in a 
storage solution for 2h at room temperature on a shaker. After 6 cycles of 10 min 
washing in TBS-T, the membrane was incubated with the HRP-conjugated secondary 
antibody diluted in blocking solution for 1 h at room temperature with constant shaking. 
The membrane was washed in 4 cycles of 10 min in TBS-T and rinsed with water. The  
membrane was incubated with ECL-detection reagent for 5 min and exposed to the 
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ChemiDocXRS camera to detect the light emitted upon the reaction of the HRP with its 
substrate contained in the ECL reagent. 
2.2.4 Generation of BMDCs 
Bone marrow cells were isolated from bones (femur and tibia) of 6-8 weeks old C57BL/6 
mice. Briefly, mice were euthanized using CO2 and hind legs were dissected. The bones 
were cleaned from muscle tissue and incubated for 1-2 min in 70% (v/v) ethanol. Then, 
the bones were rinsed in fresh RPMI medium and the ends of the bones were removed. 
The bone marrow was flushed by fresh RPMI medium pressed through the medullary 
cavity of femur and tibia. The cell suspension was transferred into falcon tubes and 
centrifuged for 10 min at 300 x g at room temperature. The supernatant was discarded 
and the pellet was re-suspended in ACK lysis buffer for 3 min. Next, 10 ml RPMI 
medium were added to stop the lysis of erythrocytes, which was followed by another 
centrifugation step for 10 min at 300 x g, at room temperature. The supernatant was 
discarded and the cell pellet was re-suspended in 10 ml RPMI medium and pressed 
through a 100 μm filter mesh. The cell number was determined as described in section 
2.2.10, adjusted to a final concentration of 1x106 cells/ml and distributed in 5x106 cells 
per well on a 6 well plate. Cell differentiation towards dendritic cells was directed by the 
presence of 5 ng/ml mouse GM-CSF in the growth RPMI medium. The cells were 
incubated at 37°C in a humidified atmosphere containing 5% CO2, with exchanging half 
of the volume per well with fresh medium every second day until day 7, when the cells 
were treated.  
2.2.5 Treatment of BMDCs 
BMDCs were treated on day 7 after the isolation from bones of mice, in GM-CSF-free 
medium. Briefly, the culture medium of cells was gently removed and replaced by fresh 
medium supplemented with 1 μg/ml LPS, 5 μg/ml c-di-AMP or cGAMP or left in medium 
without additive. Cells were incubated for 24 h at 37°C in a humidified atmosphere 
containing 5% CO2, and the cytokines present in the supernatant, surface expression of 
activation markers and intracellular presence of cytokines was analyzed. 
2.2.6 Analysis of type I IFN production by BMDCs  
The supernatants from treated BMDCs were collected, spun down and 50 μl (for IFN-β 
analysis) or 100 μl (for IFN-α analysis) of the supernatants were used per ELISA 
 Materials and methods 
  
Identification of molecular mechanisms mediating the adjuvanticity of cyclic di-nucleotides   43     
 
reaction or the samples were stored at -20°C until the analysis. The presence of IFN-α 
and -β in supernatants from treated BMDCs was evaluated using the commercially 
available IFN-β Biolegend Max ELISA kit and the VeriKineTM Mouse Interferon Alpha 
ELISA kit, according to the manufacturer´s instructions. 
2.2.7 Mouse immunization experiments 
Four or five animals per group of 9-14 weeks old mice were immunized i.n. on days 0, 
14 and 28. Animals were anesthetized with Isofluorane and 10 μl of immunization 
solution were administered per nostril. Immunization solutions were formulated in 
Ampuwa containing 15 μg OVA alone or co-administered with 5 μg of the corresponding 
CDN per dose. The control group received Ampuwa without any supplements. Animals 
were sacrificed 14 days after the third immunization and samples were collected, as 
shown in figure 7. 
 
 
Figure 7: A schematic overview of mouse immunization experiments. The picture of the 
mouse is adapted from [150]. 
2.2.8 Sample collection  
On day 42, animals were anesthetized with Isoflurane and blood samples were collected 
from the retro-orbital complex, centrifuged for 5 min at 8,000 x g, and sera were stored 
at -20°C. The mice were euthanized by exposure to CO2 and spleens and nasal lavages 
were collected. Briefly, the abdominal surface area was soaked in ethanol and the 
spleens were removed. Isolated spleens were pooled per group, transferred to complete 
RPMI medium and processed, as described in 2.2.9. The samples for analysis of IgA in 
the nasal cavity were collected by nasal washes: the lower jaw was cut and the nasal 
cavity was flushed twice with 150 μl of lavage buffer. Briefly, 200 μl pipette tip was 
inserted into a posterior opening of the nasopharynx and the wash buffer was pressed 
through the nasal cavity towards the nose entrance where it was collected in a 1.5 ml 
tube prefilled with 10 μl of 40 mM PMSF. Then, the samples were centrifuged at 7,000 x 
g for 10 min and the supernatants were stored at -20°C.  
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2.2.9 Spleen processing 
Pooled spleens of each immunization group were homogenized in complete sampling 
medium and the suspension was centrifuged for 10 min at 300 x g at room temperature. 
The supernatant was removed; the cell pellet was re-suspended and kept in ACK buffer 
for 3 min in order to lyse the erythrocytes. After 3 min, fresh medium was added to the 
suspension in order to stop the lysis and the cell suspension was centrifuged for 10 min 
at 300 x g at room temperature. Cells were re-suspended in 10 ml of fresh medium, 
pressed through a 100 μm pore cell mesh and counted.  
2.2.10 Cell counting 
The cytometer was used to determine the numbers of cells in suspensions. The cells 
were diluted with Isotone II in a ratio of 1:1000 and measured using the multisize 
analyzer and Multi32 Coulter Z2® Accu Comp® software. Everything of a size below 5 
μm was considered as debris and was not counted. Cells with a diameter between 5-16 
μm were counted.  
2.2.11 Cell proliferation assay 
Spleen cells were seeded in complete medium on 96F plates (4x105/well) in presence or 
absence of OVA (40 μg/ml), and further incubated for 72 h at 37°C in a humidified 
atmosphere containing 5% CO2. For additional 16 h cells were incubated in the 
presence of 20 μg/ml 3H-thymidine and harvested on Filtermat A filters using a cell 
harvester. Incorporated 3H-thymidine was measured by a γ scintillation counter. The 
values obtained with non-stimulated cells were subtracted from values obtained with re-
stimulated cells and the average value of replicates for each group was calculated.  
2.2.12 Detection of cytokine production in spleen cells from 
immunized mice by ELISPOT 
The production of IFN-γ, IL-2 and IL-4 by spleen cells was assessed using MultiScreen 
HTS filter plates and mouse ELISPOT pair antibodies according to the ELISPOT kit 
manufacturer´s instructions. Briefly, the plates were coated with anti-mouse IFN-γ, IL-2, 
IL-4 or IL-17 capture antibodies diluted in PBS, overnight at 4°C. Then, complete RPMI 
medium was used for washing the plates three times and blocking for 2 h at room 
temperature. Spleen cells were distributed on plates (4x105/well) and incubated in  
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complete medium with or without OVA (30 μg/ml) for 24 h (IFN-γ analysis) or 48 h (IL-2, 
IL-4, IL-17 analyses) at 37°C in a humidified atmosphere containing 5% CO2. The 
detection steps were performed according to the manufacturer´s instructions. The plates 
were scanned using a CTL ELISPOT reader and the spots were quantified using the 
ImmunoSpot image analyzer software v3.2. Spot number values of the cells without re-
stimulation were subtracted from the spot number values of the OVA-re-stimulated cells. 
The average spot number value of triplicates was calculated for each group. The 
background was always below five percent for the spot number value of the samples 
from immunization groups with OVA co-administered with adjuvants.  
2.2.13 Preparation of samples for flow cytometry analysis 
Cells for flow cytometry measurements were prepared at 4°C. The cells were incubated 
with the specified fluorophore containing reagents for 30 min. Washing steps were 
performed in PBS (except the first washing step following the intracellular staining) and 
included centrifugation for 5 min at 300 x g and 4°C. 
2.2.13.1 Preparation of spleen samples for flow cytometry analysis 
Spleen cells (12x106/well) were incubated in complete medium with or without 40 μg/ml 
OVA for 16 h at 37°C in a humidified atmosphere containing 5% CO2. For additional 8 h, 
the inhibitors of secretion brefeldin A (5 μg/ml) and monensin (6 μg/ml) were added to 
the cell suspensions. Then, cells were collected in PBS and stained with a blue 
fluorescent amine-reactive dye as a live/dead cell marker and fluorescently labeled 
antibodies: anti-mouse CD3, FITC-conjugated and CD4, PE-Cy7-conjugated. 
Afterwards, the cells were washed, fixed overnight in flow cytometry fixation buffer, 
washed again, and incubated in flow cytometry permeabilization buffer for 1 h. 
Intracellular staining was performed using anti-mouse IL-17, V-450-conjugated, and anti-
mouse TNF-α, PerCP-eFluor710-conjugated antibodies, diluted in permeabilization 
buffer. After the intracellular staining, the cells were washed in permeabilization buffer 
and two times in PBS (1 ml each wash). 
2.2.13.2 Preparation of BMDC samples for flow cytometry analysis 
BMDCs were collected in PBS and incubated for 20 min with anti-mouse CD16/32 in 
order to block the binding of fluorescently-labeled antibodies to Fc receptors present on 
the surface of the cells. For flow cytometry analysis of the surface expression of the 
activation markers, the cells were decorated with a blue fluorescent amine-reactive dye  
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as a live/dead cell marker and following fluorescent-labeled antibodies directed against 
surface markers: anti-mouse CD11c, PE-Cy7-conjugated, CD11b, eFluor450-
conjugated, MHC class II, FITC-conjugated, CD86, PE-conjugated and CD80, APC-
conjugated, diluted in PBS. Afterwards, the cells were washed three times and 
analyzed. To detect intracellular IL-6 or IL-12/IL-23p40 after 24 h of BMDC stimulation, 
the secretion inhibitors brefeldin A (5 μg/ml) and monensin (6 μg/ml) were added to the 
culture medium 16 h after starting the treatment and the cells were incubated for 
additional 8 h. Then, the cells were collected in PBS and the Fc receptors were blocked, 
as described above. The cells were stained with a blue fluorescent amine-reactive dye 
as a live/dead cell marker and fluorescently labeled antibodies: anti-mouse CD11c, PE-
Cy7-conjugated and CD11b, eFluor450-conjugated, diluted in PBS. The procedure 
following the surface staining was the same as described in 2.2.13.1 for spleen cells. 
Intracellular staining was performed using antibodies anti-mouse IL-6, PE-conjugated, 
and IL-12/IL-23p40, Alexa647-conjugated. 
2.2.14 Flow cytometry analysis 
Flow cytometry analysis was performed using an LSR-II instrument operated with the 
software FACSDiva and data was evaluated using the software FlowJo Mac v9.6. Single 
cells were gated based on their forward and sideward scatter characteristics. Live cell 
populations were identified based on their lower fluorescent signal intensity of the 
live/dead cell marker. Live CD3+/CD4+ (in the spleen cell samples) or CD11c+ (in the 
BMDC samples) single cells were selected according to the gating strategy illustrated in 
figure 8 and analyzed for enhanced fluorescence intensity indicating the antibody-
detected presence of surface activation markers MHC class II, CD86 and CD80, or 
intracellular cytokines IL-17, TNF-α, IL-6 or IL-12/IL-23p40.  
. 
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Figure 8: Gating strategy for flow cytometry data analysis. Cells measured in a constant flow 
rate were determined by gating on side scatter width (SSC-W) distribution over time (A) and were 
used for further analysis. Cell debris was excluded by gating on forward scatter area (FSC-A) 
versus side scatter area (SSC-A) (B). Doublets are characterized by high forward scatter area 
and side scatter width values. To exclude doublets based on forward scatter characteristics, cells 
were plotted FSC-A vs. FSC-H (C). The exclusion of doublets based on side scatter, cells were 
plotted for SSC-W versus SSC-A (D). Single cells were characterized by the same proportion of 
height and area. Live cells were determined based on lower fluorescence signal intensity of the 
live/dead marker, which is more intensive in necrotic cells due to penetration through the 
membranes and staining of both, cell surface and intracellular structures (E). Live cells were 
gated for cell lineage determination markers (CD11c
+
 for dendritic cells or CD3
+
/CD4
+
 for T cells) 
and were analysed for activation marker expression (surface markers or cytokine production) (F). 
2.2.15 ELISA measurement of OVA-specific IgG, IgG1 and IgG2c 
titers 
The OVA-specific IgG, IgG1 and IgG2c titers were measured by specific ELISA. High-
affinity binding 96-well plates were coated overnight at 4°C with 2 μg/ml OVA in ELISA 
coating buffer (100 μl per well) and blocked with ELISA blocking buffer for 1 h at 37°C 
(200 μl per well). Serial 2-fold dilutions of the samples (100 μl per well) were prepared in 
ELISA blocking buffer and incubated for 2 h at 37°C. ELISA blocking buffer was used as 
a blank sample. The plates were washed six times with ELISA wash buffer. The 
biotinylated detection antibody goat, anti-mouse IgG was diluted at the ratio of 1:5000 in 
ELISA diluting buffer and distributed on plates at 100 μl per well. The plates were 
incubated for 2 h at 37°C and washed again six times with ELISA wash buffer. 
Streptavidin-HRP, diluted at 1:1000 in ELISA dilution buffer was added (100 μl per well) 
and plates were incubated for 30 min at 37°C. Then, plates were washed again six times  
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with ELISA wash buffer and incubated in the dark for 15 min at room temperature with 
100 μl per well of ELISA substrate solution. The absorbance of light at 405 nm 
wavelength was measured using a Synergy 2 Multi-Mode Microplate Reader. Titers 
were determined as the highest dilution factors of the analyzed samples with at least 
twice the average readout value of the blank.  
2.2.16 ELISA measurement of total IgA and OVA-specific IgA  
The OVA-specific IgA titer was measured by ELISA with OVA-coated plates and total 
IgA titer was measured by ELISA with anti-mouse IgA-coated plates. High-affinity 
binding 96-well plates were coated overnight at 4°C with 2 μg/ml OVA or 2 μg/ml anti-
mouse IgA in ELISA coating buffer, 100 μl per well. The detection steps were performed 
as described in 2.2.15 for the measurement of IgG titers, but using a goat, anti-mouse 
IgA biotinylated antibody diluted in ELISA dilution buffer at the ratio 1:5000. ELISA 
blocking buffer was used as a blank sample. Titers were determined as the highest 
dilution factors of the analyzed samples with at least twice the average readout value of 
the blank sample (i.e. ELISA blocking buffer). Normalization was done by calculating the 
percentage of OVA-specific IgA titer of the total IgA titer determined for each sample.  
2.2.17 Statistical analysis 
Statistical analysis was performed using the unpaired t-test in GraphPad Prism 4 
software. n. s. indicates non-significant, *** indicates p<0.001, ** indicates p<0.01, 
whereas * indicates p<0.05. 
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3 RESULTS 
3.1 Ruling out artifacts due to LPS contamination of key 
immunization components  
False positive results in immunization studies can be obtained due to the presence of 
contaminations with PAMPs in immunization components. In this regard, LPS is a 
common concern as a contaminant in vaccine components. To avoid immune responses 
falsely attributed to CDN activity due to LPS contamination in stock solutions of the 
antigen OVA or adjuvants (i.e. c-di-AMP and cGAMP), the corresponding stock solutions 
were examined. To this end, a HEK-BlueTM test was applied. The reporter HEK-BlueTM-4 
cells were incubated for 24 h in medium containing the OVA, c-di-AMP or cGAMP stock 
solution. The blank sample contained endotoxin-free water. Spectrophotometric 
measurement of the absorbance at 630 nm wavelength allowed semi-quantification of 
alkaline phosphatase reporter activity, indicative for activation of the LPS-sensing 
pathway in HEK-BlueTM-4 cells. According to the report of Inagawa et al. [149], 
intravenous administration of 0.1-1 ng of LPS to mice is non-toxic, but induces a priming 
stage of innate immune cells. In our experimental model 3 μl of the OVA stock solution 
and 5 μl of the CDN stock solutions are used per immunization dose. Therefore, to 
administer the minimum reported dose of LPS that induces immunogenic effects in vivo 
(0.1 ng LPS), its concentration in the OVA stock solution would have to be higher than 
33 ng/ml or 20 ng/ml in CDN stock solutions, in case the potential LPS contamination 
would origin either from OVA or CDN stock solution. The lowest concentration of LPS 
tested in this assay was 1.6 ng/ml and the absorbance value of the samples with cells 
incubated with it was approximately three magnitudes higher than the absorbance 
measured with the cells incubated with the blank. The absorbance of the samples with 
cells incubated with immunization stock solutions were similar to the absorbance values 
of the blank (figure 9). Therefore, it was concluded that LPS was not present in stock 
solutions of OVA or CDN used in immunization studies in a concentration that could 
potentially induce immune stimulatory effects in vivo. 
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Figure 9: Absence of LPS contamination in OVA and CDN stock solutions. Stock solutions 
of OVA and CDNs were tested for the presence of LPS contamination using the HEK-Blue
TM
 test. 
Upon 24 h incubation of the reporter HEK-Blue
TM
-4 cells with either LPS at a concentration 1.6 
ng/ml, endotoxin-free water (blank) or the indicated substances, the absorbance of light at 630 
nm wavelength was measured. Error bars represent standard deviation of duplicates. 
 
 
3.2 cGAMP enhances OVA-specific humoral and cellular 
immune responses 
The immunization experiments presented in this thesis were set up in a time frame of 42 
days, where animals received primary immunization and two boosts by i.n. route, 
separated by two weeks from each other. On day 42 samples from immunized animals 
were collected and analysis of the immune response was performed. The experimental 
groups in the in vivo studies contained five animals per group. To evaluate the immune 
stimulatory potency of cGAMP, immunization studies were performed where mice were 
treated with Ampuwa, OVA alone (15 μg) or OVA (15 μg) co-administered with cGAMP 
(5 μg). Six weeks after the first application, animals were sacrificed and the samples 
were analyzed for indicators of humoral (IgG and IgA production) and cellular (spleen 
cell proliferation and cytokine production) adaptive immune responses. A schematic 
overview of the procedures is given in figure 10. 
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Figure 10: A schematic overview of the adaptive immune response evaluation strategy. 
Mice were immunized on days 0, 14 and 28. Sampling was performed on day 42 after the initial 
immunization. Nasal washes were collected for measurement of the humoral response at the 
nasal mucosa (IgA production). Serum samples were collected in order to analyse systemic 
humoral responses (IgG production). Spleen cells were re-stimulated with the antigen and their 
proliferation or cytokine production capacity was evaluated.  
 
OVA-specific immune response in animals treated with Ampuwa was barely detectable. 
The animals treated only with the antigen OVA developed a basal level of OVA-specific 
responses. The antigen-specific immune response in animals immunized with OVA and 
cGAMP was multifold enhanced, as compared to the response evoked by OVA alone 
(figure 11-13).   
Nasal wash samples from the immunized mice were analyzed to see if cGAMP co-
administration with the antigen OVA also results in enhanced OVA-specific mucosal IgA 
production. To this end, total and OVA-specific IgA were measured by ELISA and the 
amount of OVA-specific IgA was given as a percentage of total IgA. The titer of OVA-
specific IgA in nasal washes from the animals treated with OVA and cGAMP was 
significantly higher when compared to samples from animals that received OVA alone 
(figure 11 D). This finding clearly indicates the potency of cGAMP to act as a mucosal 
adjuvant. The titers of OVA-specific IgG and its sub-classes IgG1 and IgG2c were then 
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measured in serum samples of immunized animals by ELISA (figure 11 A-C). When the 
OVA-specific IgG titers were determined in serum from animals immunized with OVA 
and cGAMP, a clear trend of enhanced responses in comparison to the samples from 
the animals immunized with OVA alone was observed (figure 11 A). However, the 
differences were not statistically significant. In contrast, the OVA-specific IgG1 titer was 
significantly enhanced in serum samples from animals immunized with OVA and 
cGAMP when compared to samples from animals that received only OVA (figure 11 B). 
Similarly, the titer of IgG2c in the samples derived from animals immunized with OVA 
co-administered with cGAMP was significantly enhanced, as compared to the samples 
of mice immunized with OVA alone (figure 11 C). Elevated titers of IgG1 and IgG2c are 
indicators Th2 and Th1 cell activity, respectively [151]. Thus, the efficacy of cGAMP in 
enhancing OVA-specific IgG1 and IgG2c production implied its potency to enhance the 
activity of Th2 and Th1 cells.  
To explore the potency of cGAMP to enhance cellular responses, pooled spleen cells 
from immunized groups of animals were isolated and re-stimulated in vitro with OVA. 
First, the proliferation of spleen cells was measured using the 3H-thymidine incorporation 
assay. The cells from the animals that received OVA co-administered with cGAMP 
proliferated significantly stronger when compared to the cells from the animals that were 
immunized with OVA alone (figure 12). IFN-γ and IL-2 cytokine production are 
characteristic of Th1 cell activity, whereas IL-4 is indicative for the Th2 and IL-17 for the 
Th17 phenotype. Thus, to characterize the potential of cGAMP in enhancing Th 
responses, the production of cytokines IFN-γ, IL-2, IL-4 and IL-17 by OVA-re-stimulated 
spleen cells was measured by ELISPOT (figure 13). The numbers of IFN-γ, IL-2 and IL-
17-producing cells were significantly enhanced in samples from animals immunized with 
OVA co-administered with cGAMP when compared to cell samples derived from animals 
immunized with OVA alone (figure 13 A, B, D). Similarly, a trend of an enhanced 
number (although statistically not significant) of IL-4-producing cells was observed in 
samples from animals immunized with OVA and cGAMP, when compared to samples 
derived from animals that received OVA alone (figure 13 C). Enhanced numbers of 
antigen-specific IFN-γ, IL-2, IL-4 and IL-17-producing cells in the animals immunized 
with OVA and cGAMP in comparison to the response in mice receiving only OVA 
indicate the ability of cGAMP to enhance Th1, Th2 and Th17 responses.  
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Figure 11: cGAMP enhances antigen-specific humoral responses in immunized mice. Mice 
were treated with Ampuwa injection water or OVA alone or OVA co-administered with cGAMP. 
Serum samples of these mice were analyzed for the presence of OVA-specific (A) total IgG, (B) 
IgG1, and (C) IgG2c by ELISA. The titer gives the dilution factor of the assay sample with twice 
the readout value of the blank (absorbance of light of 405 nm wavelength). (D) Mucosal IgA was 
analyzed in nasal lavage samples by ELISA and OVA-specific IgA titers are expressed as 
percentage of the total IgA titers. The error bars represent the standard error of the mean (SEM) 
of three independent experiments with five mice per group per experiment. Significant differences 
between select groups are indicated with * for p<0.05 and ** for p<0.01, whereas n. s. indicates 
non-significant. 
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Figure 12: cGAMP enhances the antigen-specific proliferative capacity of re-stimulated 
spleen cells from immunized mice. The proliferation of antigen-stimulated spleen cells from 
mice treated with Ampuwa injection water or OVA alone or OVA co-administered with cGAMP 
was measured by a 
3
H-thymidine incorporation assay. The error bars represent the SEM of three 
independent experiments with five mice per group per experiment. Significant differences 
between select groups are indicated with * for p<0.05. 
Figure 13: cGAMP enhances IFN-γ, IL-2, IL-4 and IL-17 production of antigen-re-stimulated 
spleen cells from immunized mice. Mice were treated with Ampuwa injection water or OVA 
alone or OVA co-administered with cGAMP. Spleen cells of these mice were re-stimulated with 
OVA and analysed for the production of the cytokines (A) IFN-γ, (B) IL-2, (C) IL-4 and (D) IL-17 in 
ELISPOT assays. The results are expressed as number of spots per 10
6
 cells. The error bars 
represent the SEM of three independent experiments with five mice per group per experiment. 
Significant differences between select groups are indicated with * for p<0.05, whereas n. s. 
indicates non-significant.  
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3.3 Comparison of c-di-AMP and cGAMP immune stimulatory 
potencies  
To compare the immune stimulatory potencies of c-di-AMP and cGAMP, additional 
immunization studies were performed. Experimental groups were immunized with OVA 
alone or OVA co-administered with either c-di-AMP or cGAMP. Then, antigen-specific 
humoral and cellular responses were assessed according to the protocol shown in 
figure 10.  
3.3.1 C-di-AMP and cGAMP promote a similar enhancement of 
humoral responses 
Nasal wash samples from the immunized mice were analyzed to compare the capacity 
of c-di-AMP and cGAMP to enhance OVA-specific mucosal IgA production. To this end, 
total and OVA-specific IgA were measured by ELISA. The amount of OVA-specific IgA is 
given as a percentage of total IgA. The titers of OVA-specific IgA in nasal wash of mice 
that received CDN with OVA were significantly enhanced when compared to samples of 
mice immunized with OVA alone (figure 14 D). The extent to which c-di-AMP enhanced 
OVA-specific IgA titer was slightly higher than that observed for cGAMP (figure 14 D).  
Serum samples of immunized animals were analyzed to assess humoral responses at 
systemic level, as defined by the presence of OVA-specific IgG and its sub-classes IgG1 
and IgG2c. The titers of OVA-specific IgG in serum of mice immunized with c-di-AMP 
and OVA were significantly higher than those observed in mice immunized with OVA 
alone. A similar enhancing effect on IgG production (although statistically not significant) 
was observed in samples from animals that received the cGAMP-adjuvanted formulation 
(figure 14 A). The extent of the c-di-AMP-mediated enhancement of OVA-specific IgG 
response was slightly higher than that observed for cGAMP (figure 14 A). The titers of 
OVA-specific IgG1 in serum of mice that received either of the tested CDN with OVA 
were significantly enhanced when compared to serum of mice immunized with OVA 
alone (figure 14 B). The extent of c-di-AMP-enhanced OVA-specific IgG1 response was 
slightly higher than that observed in animals that received cGAMP as adjuvant (figure 
14 B). A clear trend of enhanced OVA-specific IgG2c titer was also observed in serum 
of mice immunized with OVA and c-di-AMP when compared to samples from mice 
immunized with OVA alone. The titer of IgG2c in serum of mice that received OVA and 
cGAMP was significantly higher as compared to samples of mice that received only 
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OVA (figure 14 C). However, the extent of c-di-AMP-mediated enhancement of OVA-
specific IgG2c response was slightly higher than that observed when using cGAMP as 
adjuvant (figure 14 C). Taken together, both candidate adjuvants enhanced the 
production of OVA-specific IgG, IgG1 and IgG2c as compared to the response observed 
in the animals immunized with the antigen OVA alone. The extent of their enhancing 
effect was comparable, with c-di-AMP being a slightly stronger enhancer of IgG, IgG1 
and IgG2c production than cGAMP. Elevated titers of IgG1 and IgG2c are indicators of 
Th2 and Th1 cell activity, respectively [151]. Thus, the capacity of c-di-AMP and cGAMP 
to promote the enhanced IgG1 and IgG2c production reported here implies that these 
candidate adjuvants promote balanced Th1/Th2 responses.     
Figure 14: Humoral response in immunized mice that received c-di-AMP or cGAMP as an 
adjuvant. Mice were treated with Ampuwa injection water OVA alone or OVA co-administered 
with either c-di-AMP or cGAMP. Serum samples of these mice were analyzed for the presence of 
OVA-specific (A) total IgG, (B) IgG1, (C) IgG2c titers by ELISA. The titers are expressed as the 
dilution factor of the assay sample with twice the readout value of the blank (absorbance of light 
of 405 nm wavelength). (D) Mucosal IgA responses were analyzed in nasal lavage samples by 
ELISA. OVA-specific IgA titers are expressed as percentage of total IgA titers. The error bars 
represent the SEM of three independent experiments with five mice per group per experiment. 
Significant differences between select groups are indicated with * for p<0.05 and ** for p<0.01, 
whereas n. s. indicates non-significant. 
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3.3.2 C-di-AMP mediates a slightly stronger enhancement of the 
proliferation capacity of spleen cells than cGAMP  
Next, cellular responses upon i.n. administration of the formulations containing OVA 
alone or co-administered with one of the two tested CDNs were measured. To this end, 
spleen cells of immunized mice were isolated and re-stimulated in vitro with OVA. The 
proliferation of cells was evaluated using the 3H-thymidine incorporation assay. The 
proliferation of OVA-re-stimulated spleen cells from mice immunized with OVA and 
either of the candidate adjuvants was significantly enhanced when compared to cell 
samples from mice immunized with OVA alone. The extent of c-di-AMP-enhanced cell 
proliferation was slightly higher than that observed for cGAMP (figure 15). 
Figure 15: Proliferation of re-stimulated spleen cells from OVA-immunized mice that 
received c-di-AMP or cGAMP as an adjuvant. The proliferation of antigen-stimulated spleen 
cells from mice treated with Ampuwa injection water, OVA alone or OVA co-administered with 
either c-di-AMP or cGAMP was measured by a 
3
H-thymidine incorporation assay. The error bars 
represent the SEM of three independent experiments with five mice per group per experiment. 
Significant differences between select groups are indicated with * for p<0.05, whereas n. s. 
indicates non-significant. 
3.3.3 C-di-AMP and cGAMP promote a similar enhancement of Th1 
and Th2 responses, but a differential activation of Th17 cells  
Cellular responses of the animals treated by i.n. route with OVA alone or combined with 
CDN were evaluated by measurement of the produced cytokines. To this end, spleen 
cells from immunized animals were re-stimulated with OVA and the production of 
cytokines was measured using ELISPOT (figure 16). The co-administration of either c-
di-AMP or cGAMP with OVA resulted in significantly enhanced numbers of IFN-γ and IL-
2-producing cells, when compared to samples derived from mice immunized with OVA 
alone (Figure 16 A-B). The number of IFN-γ-producing cells was slightly higher in  
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samples from mice that received c-di-AMP than in those receiving cGAMP as adjuvant, 
whereas the numbers of IL-2-producing cells were similar for samples derived from both 
groups (figure 16 A-B). The number of IL-4-producing cells derived from mice 
immunized with c-di-AMP and OVA was significantly higher than that observed in mice 
receiving OVA alone. A similar enhancing trend for IL-4-secreting cells (although not 
statistically significant) was observed in samples from animals that received the cGAMP-
adjuvanted formulation. Similar numbers of IL-2-producing cells were observed in mice 
receiving the c-di-AMP- and cGAMP-adjuvanted formulations (16 C). The numbers of IL-
17-producing cells were also significantly enhanced in samples from animals immunized 
with OVA and CDN when compared to samples derived from mice immunized with OVA 
alone. However, the number of IL-17-producing cells was significantly higher in mice 
receiving c-di-AMP than that observed in mice receiving the cGAMP-containing 
formulation. (Figure 16 D). 
The observation of the differential effect of c-di-AMP and cGAMP on Th17 polarization 
by ELISPOT was further investigated at the T cell subset level using flow cytometry. For 
this, OVA-re-stimulated spleen cells from mice belonging to different immunization 
groups were stained for CD3+ and CD4+ T cell surface markers and intracellular IL-17. 
This experimental approach confirmed that c-di-AMP is a stronger enhancer of the 
number of IL-17-producing cells than cGAMP. Furthermore, the application of gates for 
CD4+ cells allowed the identification of Th cells as those responsible for the differential 
production of IL-17. The frequency of IL-17-producing cells in OVA-re-stimulated 
splenocytes from mice immunized with OVA co-administered with c-di-AMP was higher 
as compared to samples derived from animals that received cGAMP as adjuvant (figure 
17). This finding indicates a clear difference in the immune stimulatory capacity of the 
two candidate adjuvants. 
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Figure 16: IFN-γ, IL-2, IL-4 and IL-17 production of re-stimulated spleen cells from OVA-
immunized mice that received c-di-AMP or cGAMP as an adjuvant. Mice were treated with 
Ampuwa injection water or OVA alone or OVA co-administered with either c-di-AMP or cGAMP. 
Spleen cells of these mice were re-stimulated with OVA and analysed for the production of the 
cytokines (A) IFN-γ, (B) IL-2, (C) IL-4 and (D) IL-17 in ELISPOT assays. The results are 
expressed as number of spots per 10
6
 cells. The error bars represent the SEM of three 
independent experiments with five mice per group per experiment. Significant differences 
between select groups are indicated with * for p<0.05 and *** for p<0.001, whereas n. s. indicates 
non-significant. 
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Figure 17: Flow cytometry analysis of IL-17 production by re-stimulated spleen cells from 
OVA-immunized mice. Mice were treated with Ampuwa injection water or OVA alone or OVA 
co-administered with either c-di-AMP or cGAMP. Pooled spleen cells from five immunized mice 
per group were re-stimulated in vitro with OVA (lower panel) or left in medium (upper panel) for 
24 h and then IL-17 production was measured by flow cytometry and results were displayed as 
dot plots. The numbers in the rectangles give the percentage of gated IL-17-producing cells 
among gated CD3
+
/CD4
+
 splenocytes. 
 
3.4 Identification of in vitro parameters indicative for c-di-AMP 
and cGAMP activity   
Some of the responses usually evoked by PAMPs at the cellular level were screened to 
identify if they can be used as surrogate in vitro parameters indicative for c-di-AMP or 
cGAMP activity using BMDCs as a model system. Hallmarks of dendritic cell activation 
are up-regulation of the surface expression of components of the immune synapsis, 
such as MHC and co-stimulatory molecules, and production of cytokines involved in 
immune activation. It was previously reported that IL-6 and IL-23, both produced by 
dendritic cells, are involved in development or maintenance of the Th17 phenotype [69, 
152]. Thus, guided by the finding that c-di-AMP and cGAMP differentially enhance Th17 
responses in vivo, it was tested if c-di-AMP and cGAMP differ in their in vitro capacity to 
induce the expression of IL-6 or IL-12/IL-23p40. In addition, it was evaluated the 
production of type I IFNs after in vitro treatment with c-di-AMP or cGAMP. To this end,  
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bone marrow cells were cultured for seven days in the presence of GM-CSF to promote 
the generation of BMDCs, and on day 7 c-di-AMP or cGAMP was added to the culture 
medium for 24 h. The surface expression of the activation markers MHC class II, CD86 
and CD80, and the production of IL-6, IL-12/IL-23p40 and type I IFNs were then 
assessed as shown in figure 18. 
 
 
Figure 18: A scheme of in vitro experiments with BMDCs stimulated with c-di-AMP or 
cGAMP. Murine bone marrow cells were cultured for 7 days in the presence of GM-CSF. The 
cells were then treated with c-di-AMP (5 μg/ml), cGAMP (5 μg/ml) or LPS (1 μg/ml) for 24 h. 
Untreated cells were used as controls. Then, BMDCs were decorated with fluorophore-
conjugated antibodies specific for dendritic cell activation markers or intracellular cytokines and 
further analysed by flow cytometry. The presence of type I IFNs was determined in supernatant 
fluids by ELISA.  
  
 
3.4.1 C-di-AMP and cGAMP exhibit a similar capacity to induce the 
surface expression of the activation markers MHC class II, 
CD86 and CD80  
Treatment of BMDCs with c-di-AMP or cGAMP for 24 h led to a clear trend of the up-
regulated surface expression of MHC class II and the T cell co-stimulatory molecule 
CD86 as compared to non-stimulated cells (figure 19). The surface expression of CD80 
by the BMDCs treated with c-di-AMP or cGAMP was also increased in comparison to 
non-stimulated cells, but to a lesser extent (figure 19). No significant differences were 
observed between the patterns of up-regulation of the activation markers expressed by 
BMDCs treated with c-di-AMP and cGAMP.  
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Figure 19: Analysis of the surface expression of activation markers on murine BMDCs 
following treatment with c-di-AMP or cGAMP by flow cytometry. BMDCs were stimulated in 
vitro with c-di-AMP (5 μg/ml) or cGAMP (5 μg/ml) or left untreated for 24 h. The cells were then 
decorated with fluorophore-conjugated antibodies specific for dendritic cell activation markers 
MHC class II (I-Ab), CD86 or CD80 and analysed by flow cytometry. Shown are the values of 
median fluorescence intensity signals measured for activation markers on CD11c
+
 cells. Error 
bars represent the SEM of four independent experiments. 
 
3.4.2 C-di-AMP is a stronger inducer of IL-12/IL-23p40 expression in 
BMDCs than cGAMP 
Next, the potential of c-di-AMP and cGAMP to induce production of IL-6 and IL-12/IL-
23p40 by BMDCs was investigated. To this end, BMDCs were treated with 5 μg/ml of c-
di-AMP or cGAMP for 24 h. Untreated cells were used as controls. During the last 8 h of 
incubation, cells were treated with inhibitors of secretion brefeldin A (5 μg/ml) and 
monensin (6 μg/ml). Subsequently, cells were processed and the fluorescence signals 
indicating the presence of cell-specific activation markers, IL-6 and IL-12/IL-23p40 were 
detected by flow cytometry. To avoid false positive results, gates indicating the cytokine-
specific signals on the CD11c+ population were set according to the position of the 
signals observed in PE (IL-6) and PE-Cy7 (CD11C)-detecting channels for non-stained 
cell samples (figure 20 B). As it is seen from the upper panel in figure 20 A, IL-6 
production in BMDCs was not observed after CDN treatment for 24 h. Nevertheless, the 
frequency of IL-12/IL-23p40+ cells in samples treated with c-di-AMP was four times the 
frequency of  IL-12/IL-23p40+ cells in untreated control samples (figure 20 A, lower 
panel). In contrast, the frequency of IL-12/IL-23p40+ cells in cGAMP-treated samples 
was only double the value observed in untreated controls (figure 20 A, lower panel). 
This observation was confirmed in three independent experiments and the statistically 
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significant difference in the potency of c-di-AMP and cGAMP to induce IL-12/IL-23p40+ 
production by BMDCs is given in figure 21. It is important to mention that p40 is a 
common subunit shared by IL-23 and IL-12. However, currently available immuno-
assays do not allow a clear distinction between these two cytokines. Therefore, it 
remains to be assessed which specific cytokine(s) (i.e. IL-12 or IL-23) is differentially 
induced by c-di-AMP and cGAMP.  
 
 
Figure 20: Analysis of IL-12/IL-23p40 induction in BMDCs upon treatment with c-di-AMP or 
cGAMP by flow cytometry. BMDCs were stimulated in vitro with c-di-AMP (5 μg/ml) or cGAMP 
(5 μg/ml) or left untreated (Medium) for 24 h. Then, BMDCs were decorated with fluorophore-
conjugated antibodies against the dendritic cell marker CD11c, as well as intracellular IL-6 (upper 
panel) an IL-12/IL-23p40 (lower panel), and cells were analysed by flow cytometry. The numbers 
in the rectangles represent the percentage of IL-6 or IL-12/IL-23p40 producing cells within the 
CD11c
+
 cell subpopulation. 
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Figure 21: Analysis of IL-12/IL-23p40 induction in BMDCs upon treatment with c-di-AMP or 
cGAMP by flow cytometry. BMDCs were stimulated in vitro with c-di-AMP (5 μg/ml) or cGAMP 
(5 μg/ml) for 24 h. Untreated cells were used as controls (Medium). The BMDCs were then 
decorated with fluorophore-conjugated antibodies against the dendritic cell marker CD11c and IL-
12/IL-23p40, and analysed by flow cytometry. Results are expressed as a percentage of CD11c
+
 
cells with intracellular expression of IL-12/IL-23p40. The error bars represent the SEM of three 
independent experiments. Significant differences between select groups are indicated with * for 
p<0.05 and ** for p<0.01, whereas n. s. indicates non-significant.  
 
3.4.3 The cGAMP is a stronger inducer of type I IFNs production by 
BMDCs than c-di-AMP 
In order to compare the capacity of c-di-AMP and cGAMP to induce expression of type I 
IFNs, BMDCs were treated with CDN and their supernatants were analyzed for the 
presence of IFN-α and IFN-β. LPS was used as a positive control of type I IFN induction. 
BMDCs were treated for 24 h with 1 μg/ml LPS (positive control), 5 μg/ml CDN or left in 
medium without additives (negative control). Supernatants were collected after 24 h 
treatment and analyzed by ELISA. BMDCs treated with LPS produced increased 
amounts of IFN-α (although the differences were not statistically significant) and 
significantly higher amounts of IFN-β, as compared to untreated controls. BMDCs 
treated with c-di-AMP produced significantly higher amount of IFNs, as compared to 
untreated samples. Similar results were obtained with BMDCs treated with cGAMP, 
which produced increased amounts of IFN-α (statistically not significant) and IFN-β, as 
compared to untreated samples. The cGAMP exhibited a slightly stronger capacity to 
induce type I IFNs expression in BMDCs than c-di-AMP, although the differences were 
not statistically significant (figure 22).   
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Figure 22: IFN-α and IFN-β production by BMDCs stimulated with c-di-AMP or cGAMP. 
BMDCs were stimulated in vitro with 1 μg/ml LPS, 5 μg/ml c-di-AMP or cGAMP or left in medium 
without additives for 24 h. Supernatants were then collected and analysed for the presence of 
IFN-α or IFN-β by ELISA. The error bars represent the SEM of three independent experiments. 
Significant differences between select groups are indicated with * for p<0.05, ** for p<0.01, 
whereas n. s. indicates non-significant. 
 
3.5 Investigation of molecular mechanisms mediating the 
adjuvanticity of CDNs 
The results obtained in BMDCs (figure 22) together with a previous study from our team 
showing the in vivo activity of c-di-AMP in IFN-β reporter mice [153] clearly demonstrate 
the capacity of c-di-AMP and cGAMP to induce type I IFNs production. This raises the 
issue of whether the stimulation of the type I IFN induction and signaling pathways is 
critical for the adjuvant properties of c-di-AMP and cGAMP. Thus, to investigate the 
impact of the type I IFN pathways on the adjuvanticity of c-di-AMP and cGAMP, 
immunization experiments were conducted using mice lacking functional Sting or 
IFNAR. This experimental approach allowed dissecting the CDN-triggered type I IFN 
pathways, namely the Sting-dependent induction of type I IFNs and IFNAR-mediated 
downstream signaling of type I IFNs resulting in the activation of ISGs. The experimental 
groups contained four or five animals and were treated with OVA or OVA co-
administered with CDN. Adaptive immune responses were assessed as described in 
figure 10. 
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3.5.1 Sting phenotyping and IFNAR-/- genotyping 
To confirm that the experimental in vivo models really lack functional components of the 
type I IFN pathways, phenotyping of the StingGt/Gt mice (Figure 23 B) and genotyping of 
the IFNAR-/- animals (figure 23 A) were performed. StingGt/Gt animals carry a single point 
mutation (T596A) of Sting that functions as a null allele and fails to produce functional, 
detectable protein [135]. This was confirmed by Western blot. SDS-PAGE/ Western blot 
analysis for Sting presence was performed on lysates of BMDCs generated from wt, 
IFNAR-/- and StingGt/G mice. Sting was detected in samples from wt and IFNAR-/- mice, 
but not in the StingGt/Gt samples (figure 23 A). Total protein staining on the nitrocellulose 
membrane using Ponceau indicated that the absence of the Sting band in the StingGt/Gt 
sample was not due to much lower total protein amounts loaded on the gel in 
comparison with the wt and IFNAR-/- samples (figure 23 B). 
 
 
Figure 23: Western blot analysis of Sting expression in BMDC lysates from wt, IFNAR
-/-
 
and Sting
Gt/Gt
 mice. (A) Image of ECL-signals recorded upon membrane exposure to a 
ChemiDocXRS camera for 39.1 sec. The arrow head indicates the Sting-specific band. (B) 
BMDCs lysates, SDS-PAGE in 10% polyacrylamide, Ponceau stained membrane. 
 
The IFNAR-/- genotype was examined by PCR and agarose gel electrophoretic analysis. 
The IFNAR1 gene disruption is characterized by a neomycin resistance gene insertion 
into the exon III in the IFNAR1 gene [148]. This resulted in sequence features that can 
be used for the identification of the knock out (ko) genotype by a detection of a specific 
PCR product (figure 24 B). DNA material was obtained from tail biopsies of wt and 
IFNAR-/- animals, which was used as template for the PCR amplification. A negative 
control, a PCR reaction containing water instead of biopsy lysate gave no detectable 
bands. Homozygous IFNAR1 gene disruption was confirmed by the presence of a 500 
bp band, whereas in wt samples a band appeared at 154 bp running distance (figure 24 
A), as expected according to the schematic overview shown in the figure 24 B.  
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Figure 24: Genotypisation of IFNAR
-/-
 animals. (A) Image of fluorescent signals indicating the 
position of PCR products after agarose gel electrophoresis. For the reactions, DNA from tissue 
lysates from wt or IFNAR
-/-
 animals was used. (B) Scheme of the IFNAR
-/-
 construct on exon III of 
the IFNAR1 gene, where a neomycin resistance gene insertion results in IFNAR1 gene 
disruption. The neomycin resistance gene is recognized by the primer 1, which in a combination 
with primer 2 upon PCR amplification results in a 500 bp fragment, confirming the IFNAR
-/-
 knock 
out genotype. Blank sample contained H2O instead of DNA template; bp indicates base pairs 
 
 
3.5.2 Sting but not IFNAR is essential for the c-di-AMP-mediated 
enhancement of the humoral immune response  
To address if the type I IFN pathways have an impact on the c-di-AMP-mediated 
enhancement of OVA-specific systemic humoral response, OVA-specific IgG titers were 
determined in serum samples of immunized mice by ELISA. To this end, the average 
titer value per experimental group was calculated, and the results were presented as 
fold of the titers detected in animals immunized with OVA alone. The obtained results 
clearly demonstrated that the c-di-AMP-mediated enhancement of the OVA-specific 
serum IgG titer observed in wt animals was lost in StingGt/Gt mice (figure 25 A). 
However, the OVA-specific IgG titers were similar in wt and in IFNAR-/- mice (figure 25 
B). 
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Figure 25: c-di-AMP enhances antigen-specific IgG responses in wt and IFNAR
-/-
, but not in 
Sting
Gt/Gt
 mice. Mice were immunized with OVA alone or OVA co-administered with c-di-AMP. 
Serum samples were then analysed by ELISA for the presence of OVA-specific total IgG. Titers 
were defined as the dilution factor of the assay sample with more than twice the readout value of 
the blank (absorbance of light of 405 nm wavelength). The average titer value per group is given 
as multiple of the value of the control group immunized with OVA alone. Results represent the 
response in wt vs. Sting
Gt/Gt
 (A) and wt vs. IFNAR
-/-
 (B). The error bars represent the SEM of 
three independent experiments where four or five animals per group were used. Statistical 
differences are indicated by ** for p<0.01, whereas n. s. indicates non-significant. 
 
3.5.3 Sting but not IFNAR is essential for c-di-AMP-mediated 
enhancement of the proliferation capacity  
The relevance of the type I IFN pathways for the c-di-AMP-mediated enhancement of 
OVA-specific cellular immune responses was evaluated. Spleen cells from immunized 
animals were re-stimulated with OVA in vitro. The proliferation of the re-stimulated cells 
was then measured using a 3H-thymidine incorporation assay. The average count per 
minute value, proportional to the amount of 3H-thymidine incorporated in cells, was 
calculated in each experimental group. Results are expressed as fold of response 
detected in animals immunized with OVA alone. The c-di-AMP-mediated enhancement 
of cell proliferation was considerably reduced in StingGt/Gt mice, as compared to values in 
samples from wt animals (figure 26 A). In contrast, the extent of c-di-AMP-enhanced 
proliferation of OVA re-stimulated spleen cells derived from wt animals was similar to 
that observed in samples from IFNAR-/- mice (figure 26 B). 
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Figure 26: Incorporation of c-di-AMP in the immunization formulation results in enhanced 
antigen-specific proliferation of spleen cells from wt and IFNAR
-/-
, but not Sting
Gt/Gt
 mice. 
Spleen cells from mice immunized with OVA alone or co-administered with c-di-AMP were re-
stimulated with OVA and analysed for their proliferative capacity using a 
3
H-thymidine 
incorporation assay. The average value of the replicates in each group is given as multiple of the 
average value of the control group immunized with OVA alone. The error bars represent the SEM 
of three independent experiments where four or five animals per group were used; n. s. indicates 
non-significant. 
3.5.4 Sting but not IFNAR is crucial for the c-di-AMP-mediated 
enhancement of Th1, Th2 and Th17 responses  
To characterize the role played by the type I IFN pathways in the c-di-AMP-mediated 
enhancement of Th immune responses, the well accepted indicators of Th1 (IFN-γ, IL-2) 
or Th2 (IL-4) activity were determined. To this end, the production of cytokines by OVA-
re-stimulated spleen cells obtained from wt mice and animals lacking functional Sting or 
IFNAR was measured using ELISPOT post immunization. The c-di-AMP-mediated 
enhancement in the numbers of IFN-γ, IL-2 and IL-4-producing cells observed in wt 
animals was lost in samples derived from StingGt/Gt mice (figure 27, left panel). In 
contrast, the results obtained in IFNAR-/- animals immunized with OVA and c-di-AMP 
showed a clear trend of higher numbers of IFN-γ, IL-2 and IL-4-secreting cells as 
compared to samples from wt mice (figure 27, right panel).  
Additional studies were performed to assess the production of selected cytokines in the 
CD4+ T cell subset. To this end, intracellular staining of OVA-re-stimulated splenocytes 
was performed to evaluate the production of IL-17 and TNF-α in CD3+/CD4+ cells using 
flow cytometry. The c-di-AMP-mediated enhancement in the frequency of IL-17 positive 
cells within the CD3+/CD4+ cell fraction observed in wt mice was abolished in the 
samples obtained from StingGt/Gt animals, while it was preserved in IFNAR-/- mice-
derived samples (figure 28 A).  Similarly to what was observed for the IFN-γ, IL-2 and 
IL-4 cytokine responses in the ELISPOT assay (figure 27, right panel), in samples from 
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IFNAR-/- mice immunized with OVA and c-di-AMP a clear trend of higher frequency of IL-
17-producing cells was observed when compared to samples derived from wt animals 
(figure 28 A). The c-di-AMP-mediated enhancement in the frequency of TNF-α positive 
cells within the CD3+/CD4+ cell fraction observed in wt mice was abolished in the 
samples derived from StingGt/Gt animals, whereas similar responses were detected in wt 
and IFNAR-/- animals (figure 28 B). 
 
Figure 27: The c-di-AMP-mediated enhancement of IFN-γ, IL-2 and IL-4 responses is lost in 
Sting
Gt/Gt 
but not in
 
IFNAR
-/-
 mice. Spleen cells from mice immunized with OVA alone or co-
administered with c-di-AMP were re-stimulated with OVA and analyzed for specific cytokine 
production: IFN-γ (A), IL-2 (B) and IL-4 (C) using the ELISPOT assay. The results are expressed 
as average number of spots per 10
6 
cells. The error bars represent the SEM of four (Sting
Gt/Gt
) or 
three (IFNAR
-/-
) independent experiments where four or five animals per group were used. 
Statistical differences are indicated by * for p<0.05, ** for p<0.01, whereas n. s. indicates non-
significant. 
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Figure 28: The c-di-AMP-mediated enhancement of IL-17 and TNF-α production is lost in 
Sting
Gt/Gt
 but not in IFNAR
-/-
 mice. Mice were immunized with OVA alone or co-administered 
with c-di-AMP. Spleen cells of the immunized mice were re-stimulated with OVA and analysed for 
the production of IL-17 (A) and TNF-α (B) by flow cytometry. Plots show the percentage of cells 
with intracellular fluorescent signals indicating the presence of IL-17 or TNF-α within gated 
CD3
+
/CD4
+
 cells. Error bars represent SEM of three (Sting
Gt/Gt
) or two (IFNAR
-/-
) independent 
experiments where four or five animals per group were used. Statistical differences are indicated 
by * for p<0.05 and ** for p<0.01, whereas n. s. indicates non-significant. 
3.5.5 The role of Sting and IFNAR in the adjuvantictiy of cGAMP  
To address the role played by the type I IFN pathways on the cGAMP-mediated 
enhancement of the adaptive immune responses, immunization experiments were 
performed in mice lacking a functional Sting or IFNAR. Animals were immunized with 
OVA or OVA co-administered with cGAMP and the immune responses were assessed 
according to the description given in figure 10. The data shown here represent three 
independent experiments in which the immune responses were compared in wt and 
StingGt/Gt animals, and one experiment in which responses in wt and IFNAR-/- animals 
were assessed. Each experiment contained four or five animals per group. 
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3.5.5.1 Sting is essential for cGAMP-mediated enhancement of antigen-
specific IgG responses  
To assess the impact of the type I IFN pathways on the cGAMP-mediated enhancement 
of humoral immune responses, OVA-specific IgG titers were determined in sera of 
immunized mice by ELISA. Average titer per experimental group was calculated and 
results were expressed as fold of the response detected in animals immunized with OVA 
alone. The obtained results demonstrated that, as observed for c-di-AMP, cGAMP-
mediated enhancement of OVA-specific IgG response was lost in StingGt/Gt mice (figure 
29).  
 
Figure 29: cGAMP enhances antigen-specific IgG responses in wt, but not in Sting
Gt/Gt
 
mice. Mice were immunized with OVA alone or OVA co-administered with cGAMP. Serum 
samples were then analyzed by ELISA for the presence of OVA-specific total IgG. Titers were 
defined as the dilution factor of the assay sample with more than twice the readout value of the 
blank (absorbance of light of 405 nm wavelength). The average titer value in each group is given 
as a multiple of the value in the control group in which mice were immunized with OVA alone. 
Results representing the response in wt vs. Sting
Gt/Gt
 are shown. The error bars represent the 
SEM of three independent experiments where four or five animals per group were used. 
Statistical difference is indicated by * for p<0.05. 
 
Subsequently, the immune responses were evaluated in IFNAR-/- mice. A preliminary 
experiment with four animals per group suggested that cGAMP-mediated enhancement 
of the OVA-specific IgG response in IFNAR-/- animals was slightly reduced when 
compared to that observed in wt animals (figure 30). However, it was also clear that 
there is a residual retained adjuvanticity. Thus, it seems that type I IFN signaling 
contributes to some extent to the adjuvant activity of cGAMP. 
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Figure 30: Antigen-specific IgG responses in wt and IFNAR
-/-
 mice immunized with OVA 
alone or in a combination with cGAMP. Serum samples were analyzed by ELISA. For OVA-
specific total IgG the titer was defined as the dilution factor of the assay sample with more than 
twice the readout value of the blank (absorbance of light of 405 nm wavelength). The average 
titer values of samples from individual animals are represented as columns. In the experiment 
were used four animals per group. 
 
3.5.5.2 Sting is essential for cGAMP-mediated enhancement of Th1, Th2 
and Th17 responses  
Next, the indicators of Th1 (IFN-γ, IL-2), Th2 (IL-4) and Th17 (IL-17) activity were 
measured to assess the dependency of the cGAMP-mediated enhancement of Th 
responses on functional components of the type I IFN pathways. Thus, the production of 
cytokines by OVA-re-stimulated spleen cells from immunized wt mice and animals 
lacking functional Sting or IFNAR was measured using ELISPOT. The cGAMP-mediated 
enhancement in numbers of IFN-γ, IL-2, IL-4 and IL-17-producing cells observed in wt 
mice was lost in samples derived from StingGt/Gt animals (figure 31). According to the 
results of the preliminary experiment using IFNAR-/- animals, cGAMP-mediated 
enhancement in numbers of IL-2, IL-4 and IL-17 producing cells seem to be preserved 
(figure 32 B-D), whereas the number of IFN-γ producing cells was reduced as 
compared to the values observed in wt animals (figure 32 A). This suggests that 
cGAMP-mediated activation of type I IFN contributes to Th1 polarization. 
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Figure 31: cGAMP enhances IFN-γ, IL-2, IL-4 and IL-17 production by OVA-re-stimulated 
spleen cells from immunized wt, but not Sting
Gt/Gt
 mice. Spleen cells from mice immunized 
with OVA alone or co-administered with cGAMP were re-stimulated with OVA and analyzed for 
specific cytokine production: IFN-γ (A), IL-2 (B), IL-4 (C) and IL-17 (D) using the ELISPOT assay. 
The average number of spots is given for 10
6 
cells. The error bars represent the SEM of four 
independent experiments where five animals per group were used. Statistical differences are 
indicated by * for p<0.05, ** for p<0.01, *** for p<0.001, whereas n. s. indicates non-significant. 
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Figure 32: IFN-γ, IL-2, IL-4 and IL-17 production by OVA-re-stimulated spleen cells from wt 
and IFNAR
-/-
 animals immunized with OVA alone or in a combination with cGAMP. Spleen 
cells from immunized mice were re-stimulated with OVA and analyzed for cytokine production: 
IFN-γ (A), IL-2 (B), IL-4 (C) and IL-17 (D) using the ELISPOT assay. The average number of 
spots is given for 10
6 
cells. The columns represent average value of triplicates in one preliminary 
experiment where four animals per group were used.  
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4 DISCUSSION  
The major objectives of this thesis were to: i) evaluate the adjuvant properties of 
cGAMP, ii) compare the immune modulatory properties of c-di-AMP and cGAMP and iii) 
investigate the role played by type I IFN induction and signaling pathways in the 
adjuvanticity of c-di-AMP and cGAMP. These questions were answered by performing in 
vivo immunization studies, where the model antigen OVA was applied by i.n. route alone 
or co-administered with CDN to wt mice or animals lacking functional Sting or IFNAR. 
After the completion of the immunization schedule, OVA-specific humoral and cellular 
responses were characterized. In addition, in vitro studies using BMDCs were performed 
to identify the parameters indicative for c-di-AMP and cGAMP immune stimulatory 
activity. 
4.1 cGAMP is a potent candidate mucosal adjuvant able to 
evoke balanced humoral and cellular immune responses 
In this thesis it was asked if cGAMP has immune modulatory properties when used as 
adjuvant. Immunization experiments were performed in which the model antigen OVA 
was administered alone or together with cGAMP to mice and the resulting adaptive 
immune responses were evaluated. Collectively, these data demonstrate the potency of 
cGAMP to enhance antigen-specific humoral and Th1/Th2/Th17 responses (figure 11-
13).   
The increased production of specific IgA and IgG in animals treated with OVA and 
cGAMP as compared to mice receiving OVA alone (figure 11) demonstrates the 
adjuvant properties of cGAMP in terms of evoking enhanced antigen-specific humoral 
responses at mucosal and systemic levels. Production of secretory IgA is a hallmark of 
adaptive mucosal immunity and its ability to block the colonization of mucosal surfaces 
by pathogens contributes to prevent infections. Therefore, the ability of cGAMP to 
enhance the production of antigen-specific IgA suggests it as a promising tool to 
promote local protection at the mucosa. Re-stimulated spleen cells from animals 
immunized with OVA combined with cGAMP showed enhanced antigen-specific 
proliferation capacity (figure 12), indicating that the incorporation of cGAMP into the 
immunization formulation can also potentiate cellular immune responses. Additional 
studies showed that the production of IFN-γ and IL-2 (indicators of Th1 response), IL-4 
(indicator of Th2 response) and IL-17 (indicator of Th17 response) was also improved in 
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re-stimulated spleen cells from animals that received OVA and cGAMP (figure 13). This 
demonstrates the ability of cGAMP to act as an enhancer of balanced Th1/Th2/Th17 
responses. Th2 cell activity is known to promote Ig class switch in B cells to produce 
IgG1, whereas Th1 cell activity promotes Ig class switch leading to IgG2c production. 
Thus, the enhanced production of cytokines indicative for Th1 and Th2 responses is in 
agreement with the observed increment of IgG2c and IgG1 production in animals 
immunized with OVA and cGAMP (figure 11 B-C). The model antigen OVA is described 
as a week immunogen [154], thereby mimicking the poor immunogenicity of antigens 
incorporated in subunit vaccines. Here, it was demonstrated that co-administration of 
cGAMP with OVA promotes a strong enhancement of OVA-specific humoral and cellular 
immune responses, suggesting its use as a valid candidate adjuvant for subunit 
vaccines. The desired vaccine-evoked immune response highly depends on the 
pathogen´s life style. Currently available vaccines promote a polarized humoral immune 
response that is sufficient to fight only some of the pathogens. For example, a vaccine-
evoked long lasting humoral response sustained by Th2 cells is closely related to the 
protection against extracellular pathogens, such as Corynebacterum diphteriae, 
Clostridium tetani and Bordetella pertussis [155]. However, an immune response profile 
based only on antibody production is suboptimal in fighting pathogens that are not 
accessible to antibodies or in cases when both, antibody and cellular responses, such 
as Th17 [156-159] are required. The described cGAMP-mediated humoral and Th17 
responses suggest a possible application of cGAMP in the development of vaccines 
against pathogens that need antibodies and Th17 responses to be fought, such as 
pneumococci [156]. To protect the host from intracellular pathogens hidden from 
antibodies inside of invaded cells, CTL activity is required (e.g. M. tuberculosis, S. 
typhimurium, T. gondii, human immunodeficiency virus). CTL development depends on 
the Th1 response. Therefore, the potency of cGAMP to enhance the Th1 response 
suggests its application in vaccines to fight intracellular pathogens. In addition to the 
demonstrated in vivo adjuvant efficacy of cGAMP in mice, its potency to activate human 
dendritic cells was reported [140]. This further supports the potential of cGAMP as a 
candidate adjuvant for human vaccines.  
The cGAMP used in the studies presented in this thesis is a bacterial (3´,5´) isomer of 
the (2´, 5´)-cGAMP that is present in the cytosol of mammalian cells. The results 
presented here demonstrate that cGAMP can act as a PAMP, when administered 
extracellularly. For the (2´, 5´)-cGAMP Li et al. showed in a short term immunization 
experiment that intramuscular immunization of mice with OVA co-administered with 
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(2´,5´)-cGAMP enhanced the production of antigen-specific IgG1 in serum and IFN-γ 
and IL-2 by re-stimulated spleen cells, indicating its immune modulatory potential [160]. 
So far, the only known signaling axis that includes (2´,5´)-cGAMP is dsDNA-triggered 
cGAS-mediated (2´,5´)-cGAMP production that results in Sting-dependent IFN-β up-
regulation [17, 18, 33-36]. Now, it is evident that even extracellular application of the 
cGAMP or (2´,5´)-cGAMP modulates the immune response. However, it is not known to 
which extent IFN-β is involved and what other pathways possibly contribute to their 
adjuvanticity. In this regard, it would be interesting to evaluate if the adjuvanticity of 
cGAMP and (2´,5´)-cGAMP rely on the same mechanisms, as well as to evaluate if 
there are any differences in terms of the molecular mode of action with respect to c-di-
AMP and c-di-GMP (further discussed in the chapter 4.3).  
4.2 The c-di-AMP and cGAMP exhibit different effector 
functions, rendering them as potential tools for fine-tuning 
immune responses following vaccination 
Immunization experiments using OVA as a model antigen and c-di-AMP or cGAMP as 
adjuvants were further conducted in mice in order to explore the potential of the 
candidate adjuvants as tools for evoking differential immune responses. The data 
generated demonstrate that c-di-AMP is a more robust candidate adjuvant than cGAMP. 
In fact, slightly stronger humoral and Th1/Th2 responses were observed when using c-
di-AMP as adjuvant as compared to those observed in mice receiving cGAMP (figures 
14-17). In addition, c-di-AMP also exhibits a significantly higher potency to enhance 
Th17 responses than cGAMP. 
OVA-specific humoral immune responses of the immunized animals were quantified as 
titers of IgA and IgG. The incorporation of c-di-AMP or cGAMP in the immunization 
formulation resulted in enhanced titers of OVA-specific mucosal IgA and systemic IgG 
and its subclasses IgG1 and IgG2c (figure 14), although slightly higher titers were 
obtained when using c-di-AMP. The proliferation capacity of antigen-re-stimulated 
spleen cells was also enhanced by both, c-di-AMP and cGAMP (figure 15). The same 
was true for the numbers of antigen-specific cells producing IFN-γ and IL-2 (indicative 
for the Th1 cell phenotype) and IL-4 (indicative for the Th2 cell phenotype) (figure 16 A-
C). However, also here a trend can be observed for slightly superior responses, 
although statistically non-significant, in animals receiving c-di-AMP as adjuvant. Th1 
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activity promotes the development of a CTL response that is important to fight 
intracellular pathogens. Both, c-di-AMP and cGAMP enhance Th1 responses (Figure 16 
A-B), suggesting their use in vaccines fighting intracellular pathogens, which is barely 
achievable with currently available alum-containing vaccines [161].  
The analysis of the IL-17 responses in immunized animals revealed that c-di-AMP is a 
more potent enhancer of Th17 responses than cGAMP (figure 16 D, 17). IL-17 signaling 
can modulate Th1 responses [162] and mucosal immunity. It upregulates polymeric Ig 
receptor levels in mucosal epithelia [163] and promotes B-cell differentiation into IgA-
secreting cells [164]. Interestingly, only minimal differences were observed in the Th1 
and IgA responses promoted by c-di-AMP and cGAMP. This suggests that under our 
experimental conditions Th1 profiles and mucosal IgA responses do not depend on IL-
17. One of the general goals of vaccination is to promote effector mechanisms leading 
to an efficient protective response without evoking mechanisms leading to potential 
adverse effects. This is a quite challenging task because the induction of the wrong Th 
profile in a particular context can lead to severe health problems. For example, a Th17 
response seems to be required for vaccine-mediated protection against some 
pathogens (e.g. Pseudomonas aeruginosa, M. tuberculosis and S. pneumonia) [156, 
159, 165-167]. However, a deregulated IL-17 production is responsible for immune 
pathology in chronic inflammatory and autoimmune diseases [168-170]. In this regard, 
arthritis is an IL-17-linked autoimmune disease that can develop after immunization and 
challenge with Borrelia burgdorferi in mice [171]. Furthermore, IL-17 production is 
related to the maintenance of encephalomyelitis in a murine model [172]. Thus, to 
minimize the health risks related to unnecessary induction of IL-17, cGAMP could be 
used in vaccine formulations for the pathogens where a strong Th17 response is not 
really needed, whereas c-di-AMP would be beneficial for the formulations against 
pathogens where it is needed for optimal host protection.  
An important aspect of vaccine development is to reduce the risk of failure of candidate 
vaccines in late stages of clinical trials. Elucidation of the signaling network mediating 
the immune stimulatory effects of CDNs may facilitate the prediction of their safety 
profile and efficacy in humans. As a precondition to investigate the molecular 
mechanisms of their action, it is necessary to identify parameters indicative for CDN 
activity in vitro. Strong up-regulation of the surface expression of MHC class II and 
CD86, and induction of type I IFNs and IL-12/IL-23p40 expression in BMDCs after 
treatment with CDNs qualify these parameters and BMDCs as a suitable system for in  
 
 Discussion 
 
 80          Identification of molecular mechanisms mediating the adjuvanticity of cyclic di-nucleotides 
vitro investigation of CDNs (figure 19-22). The identified markers of CDN activity can be 
used as readouts in future studies using specific inhibitors, allowing identification of 
molecular pathways triggered by CDNs. In the studies presented here, the treatment of 
BMDCs with CDNs did not result in IL-6 production (figure 20 A, upper panel). This 
could be explained by two main reasons: i) IL-6 expression is not affected by the 
treatment of BMDCs with CDNs or ii) the applied experimental strategy was suboptimal 
for IL-6 detection. Kinetic analysis of IL-6 induction by CDNs would allow verifying if IL-6 
is produced at an earlier time point than 16 h upon treatment, time at which the inhibitors 
of secretion were added to the cells. On the other hand, c-di-AMP was identified as a 
more potent inducer of IL-12/IL-23p40 expression in BMDCs than cGAMP (figure 21, 20 
A, lower panel). The p40 is a common protein subunit shared by IL-23 (p19p40) and IL-
12 (p35p40) [173]. The used detection antibody against p40 does not allow distinction 
between IL-23 and IL-12. Therefore, the observed differences in IL-12/IL-23p40 
expression by BMDCs after treatment with c-di-AMP and cGAMP cannot be exclusively 
attributed to either of these cytokines. Distinction between the two cytokines could be 
achieved by simultaneous detection of the p19 or p35 with the p40 subunit. However, 
flow cytometry assays allowing a reliable distinction between the IL-12 and IL-23 based 
on simultaneous detection of p19 or p35 with p40 need to be developed. Studies 
focused on specific detection of IL-12 and IL-23 mRNA may clarify which cytokine is 
affected by CDN treatments. The p40 can be present in a form of monomers or dimers 
and their ratio determines the bioactivity of IL-12 [174]. The p40 homodimer acts as a 
suppressor of IL-12 activity. IL-12 is a Th1 phenotype-promoting cytokine [175]. The 
results presented here (figure 14 C, 16 A-B) do not indicate strong differences in the 
capacity of c-di-AMP and cGAMP to enhance Th1 responses, as measured by the 
increase in IgG2c titers and the number of IFN-γ and IL-2 producing cells. Therefore, if it 
turns out that c-di-AMP and cGAMP differentially induce the IL-12 production further 
experiments will be needed to identify an immune response branch, other than Th1, that 
may be affected by the CDN-triggered production of IL-12. On the other hand, IL-23 
seems to be important for the maintenance of Th17 response [68, 69]. Therefore, if the 
studies show that c-di-AMP and cGAMP can differentially affect IL-23 production by 
BMDCs, this could point to the underlying molecular mechanism for differential 
enhancement of Th17 responses observed in vivo.     
Taken together, evoking balanced humoral and cellular responses with a fine-tuned 
level of IL-17 production is important for fighting many pathogens, but it is barely 
achievable with currently approved adjuvants. The results shown in this thesis indicate 
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c-di-AMP and cGAMP as a possible solution for this problem because both of them 
promote humoral and Th1/Th2 responses at similar and Th17 response at different 
levels. Therefore, depending on the need for a robust Th17 response, one could use c-
di-AMP or cGAMP in vaccines. The identified parameters indicative for the c-di-AMP 
and cGAMP activity in vitro are crucial for further exploration of the pathways 
responsible for their adjuvanticity. To this end: i) specific indicators of the c-di-AMP or 
cGAMP activity in vitro can be used as readouts for elucidation the molecular 
cascade(s) triggered by CDNs resulting in up-regulation of a specific indicator or ii) in 
vivo studies using ko models can be applied to address if a specific indicator of the c-di-
AMP or cGAMP activity in vitro is actually relevant for their efficacy as adjuvants. In this 
thesis, in vivo studies were conducted to address the relevance of type I IFN induction 
and signaling pathways for the adjuvanticity of c-di-AMP and cGAMP. 
4.3 Sting is essential for the adjuvanticity of c-di-AMP and 
cGAMP 
To address if the activation of type I IFN induction and signaling pathways was required 
for the adjuvant activities of c-di-AMP and cGAMP, immunization experiments were 
performed using mice lacking functional Sting or IFNAR. The data characterizing the 
humoral and cellular immune responses enhanced by the two candidate adjuvants 
shows that Sting is required for the adjuvanticity of c-di-AMP (figure 25-28) and cGAMP 
(figure 29, 31). In contrast, IFNAR signaling seems to be dispensable for the 
adjuvanticity of c-di-AMP (figure 25-28) and, to some extent, also for cGAMP (figure 
30, 32). 
Th cells are central players of the adaptive immunity. The c-di-AMP-mediated 
enhancement in the production of Th1, Th2 and Th17 cytokines was significantly 
impaired in StingGt/Gt animals, whereas it was preserved in animals lacking functional 
IFNAR signaling (figure 27, 28 A). Similarly, cGAMP-mediated enhancement of Th1, 
Th2 and Th17 responses was impaired in StingGt/Gt animals (figure 31). Preliminary 
experiments using cGAMP suggested that enhanced IL-2, IL-4 and IL-17 responses are 
preserved in IFNAR-/- animals, whereas IFN-γ is reduced (figure 32). For c-di-GMP, 
Blaauboer et al. reported that enhanced humoral as well as Th responses were 
abolished in StingGt/Gt mice, whereas in IFNAR-/- mice they were enhanced to the same 
extent as those observed in wt animals [147].   
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Interestingly, IFNAR-/- animals immunized with the antigen co-administered with c-di- 
AMP have increased numbers of IL-4-producing T cells as compared to wt mice (figure 
27 C). This suggests an enhanced c-di-AMP-mediated Th2 activity in the absence of 
IFNAR signaling. This is in agreement with studies from Huber et al. describing type I 
IFN as a suppressor of Th2 responses, one of the major factors shaping the 
development of neutralizing antibodies [176]. Furthermore, a tendency of enhanced 
production of the Th1 indicators IL-2 and IFN-γ by  IFNAR-/- animals was observed, 
whereas the TNF-α induction was the same as in wt animals immunized with the antigen 
and c-di-AMP (figure 27 A-B, 28 B). A trend of enhanced c-di-AMP-mediated Th17 
response in IFNAR-/- animals was also observed in comparison to wt animals (figure 28 
A). This could be due to an IFNAR-mediated suppression of the Th17 response, 
previously reported by Guo et al. [177]. Interestingly, no tendency towards an enhanced 
c-di-GMP-mediated Th1, Th2 and Th17 responses was observed in IFNAR-/- animals, 
when compared to responses in wt mice, as reported by Blaauboer et al. [147]. The 
same seems to be true for cGAMP in the preliminary experiment shown in figure 32. In 
fact, it also seems that the expansion of IFN-γ-producing cells is partially impaired in 
IFNAR-/- mice immunized using cGAMP as adjuvant. Therefore, the enhanced 
production of Th cytokines in the absence of IFNAR signaling seems to be a unique 
feature of c-di-AMP-adjuvanted immune responses.  
Several reports described the potential of type I IFNs as enhancers of neutralizing 
antibody development [178-181]. Here, the c-di-AMP mediated enhancement of the 
systemic antigen-specific IgG response was dependent on Sting, but not on IFNAR 
(figure 25). This result resembles the phenotype previously published [147], describing 
the lack of Sting as severely impairing the humoral responses enhanced by c-di-AMP. 
IL-4 production is a hallmark of Th2 activity which promotes the humoral response. 
Interestingly, a trend of enhanced c-di-AMP-mediated IgG response in IFNAR-/- animals 
was not observed when compared to wt mice, despite the fact that the enhanced 
number of IL-4-producing cells in IFNAR-/- mice was higher than that in wt animals 
(figure 27 C). 
In the preliminary experiment using cGAMP, Th2 and Th17 responses in IFNAR-/- 
animals were enhanced by cGAMP to a similar extent to those observed in wt animals 
(figure 32 C-D). In contrast, the Th1 response was partially impaired, as indicated by a 
reduced IFN-γ production (figure 32 A). The IgG titers were also lower in IFNAR-/- 
animals immunized with OVA and cGAMP than in wt animals (figure 30). Therefore, it 
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seems that IFNAR might be required for cGAMP-mediated enhancement of IgG and Th1 
responses. Similarly, in a short term immunization experiment using eukaryotic (2´,5´)- 
cGAMP, Li et al. reported significantly impaired IgG1 response in StingGt/Gt mice and 
reduced response in IFNAR-/- animals as compared to the response observed in wt 
animals [160]. Taken together, this data suggests that IFNAR-mediated signaling may 
differentially modulate the immune response profiles according to the specific CDN: 
down-regulation of c-di-AMP-mediated Th responses and the promotion of c-GAMP-
mediated IgG and IFN-γ production.   
Taken together, obtained results demonstrated that Sting is a crucial mediator of the 
adjuvanticity of c-di-AMP and cGAMP, suggesting that in this process Sting functions 
beyond its ability of inducing the production of type I IFNs. Although IFNAR is in part 
dispensable, IFNAR-mediated signaling seems to modulate the extent of c-di-AMP- and 
cGAMP-mediated enhancement of immune responses. The exact mechanisms of this 
modulation remain to be elucidated. Based on these findings and currently available 
knowledge on the stimulation of immune responses via the mucosa, a model of the c-di-
AMP-mediated stimulation of immune responses following i.n. administration is 
proposed in figure 33. First, the antigen and c-di-AMP administered into the nasal cavity 
are transported from the apical to the basolateral side of the mucosal epithelium to 
reach the APCs which are part of the NALT. Most likely, this transport is done via M cell-
mediated transcytosis. Then, OVA is internalized by APCs, processed and its peptides 
are presented on their surface in the context of MHC class II molecules that will allow 
the activation of OVA-specific T and B cells. Simultaneously, c-di-AMP triggers signals 
that lead to enhanced OVA-specific antibody production and Th1/Th2/Th17 cell 
development, characterized as a balanced immune response. This response is 
completely dependent on c-di-AMP-triggered activation of Sting, which is located in the 
membrane of ER. This implies that c-di-AMP has to be delivered to the cytosol of APCs, 
but does not exclude its potential to trigger signaling as well from the surface of APCs. It 
is not clear if c-di-AMP activates Sting by direct binding or indirectly. The presence of c-
di-AMP also results in an enhanced surface expression of MHC class II, CD86 and 
CD80. This in turn, boosts the power of APCs to activate the naïve T and B cells present 
locally in the NALT. APCs also migrate to regional lymph nodes where they can cross-
talk and activate naïve T and B cells. These initial events lead to the initiation of a 
balanced adaptive immune response, strongly dependent on Sting, but to a large extent 
independent of the biological activities of type I IFN.  
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Figure 33: A model of the c-di-AMP-mediated enhancement of OVA-specific immune 
responses. Mice immunized by i.n. route with OVA co-administered with c-di-AMP as adjuvant 
develop enhanced adaptive immune responses (i.e. antibody production, Th1, Th2, Th17). OVA 
and c-di-AMP are administered into the nasal cavity of a mouse and have to cross the epithelium 
in the NALT from the apical side to the basolateral side (transcytosis) to reach APCs. APCs 
process OVA and c-di-AMP enhances their power to promote an OVA-specific immune response. 
The c-di-AMP-mediated activation of APCs is Sting-dependent and IFNAR-independent. The Th1 
response promotes the development of cytotoxic T lymphocytes (CTL). Th2 response promotes 
the activation of B cells and production of protective antibodies (Ig). The picture of the mouse and 
the graphics of the NALT epithelium are adapted from  [150] and [108], respectively. 
 
Starting from the idea that IFN type I acts predominantly at the innate level to fight 
pathogens, it would be dispensable in a vaccination situation, when the goal is to build 
up an adaptive immune protection against a future encounter of a specific pathogen 
rather than evoking, for example, a direct antiviral response. However, the conclusions 
on the role of IFNAR-mediated signaling in the adjuvanticity of c-di-AMP presented in 
this thesis are based on measurements of humoral responses and Th cell activity.  
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The role of IFNAR in the c-di-AMP-mediated induction of long term memory and 
enhancement of a cytotoxic CD8+ T cell response remains to be explored. Type I IFN 
may indirectly contribute to CD8+ T cell priming. Archer et al. suggested that type I IFN 
suppresses L. monocytogenes-specific CD8+ T cell priming via unknown mediators 
[146]. On the other hand, Zhang et al. suggested that the role of type I IFN in the 
development of a CD8+ memory phenotype is mediated by IL-15 [182]. In this regard, it 
would be interesting to compare the potency of c-di-AMP to induce IL-15 secretion by 
APCs and to perform measurements of CTL activity in wt and IFNAR-/- animals to test if 
IFNAR is involved in c-di-AMP-mediated stimulation of CTL responses.   
It has been described that Sting can activate IRF3 and/or NF-κB in a TBK-1-dependent 
manner, thereby resulting in IFN-β and/or TNF-α production [183]. This is in addition to 
its capacity to trigger ERK activation, as reported by Jin et al. [26]. Blaauboer et al. 
described that the non-canonical NF-κB activation by Sting results in TNF-α production 
[147]. This in turn acts via the tumor necrosis factor receptor (TNFR)1, being the critical 
mediator for the mucosal adjuvanticity of c-di-GMP and the IgG responses enhanced by 
c-di-AMP. However, the preserved enhancement of Th17 responses and the residual 
Th1, Th2 and humoral responses observed in TNFR1-/- animals suggest that molecular 
pathways functioning as mediators of the adjuvanticity of c-di-GMP cannot not be 
restricted to the alternative NF-κB-TNF-α pathway.   
Negative [28, 30, 31, 184] and positive [29] regulators of Sting activity have been 
described. Some of them even differentially affect the ability of Sting to trigger IFN-β or 
TNF-α production [185], indicating that Sting activation may result in different cytokine 
profiles due to its regulation. In this thesis it was reported that the Th17 response is 
differentially enhanced by c-di-AMP and cGAMP (figure 16 D, 17) and Sting is critical 
for their ability to enhance Th17 responses (figure 28 A, 31 D). Therefore, it would be 
interesting to explore if the differential enhancement of the Th17 response is a result of 
c-di-AMP and cGAMP interactions with different regulators of Sting. 
4.4 Sting as a central molecule mediating the CDN immune 
stimulatory activity 
Overstimulation of Sting can result in a chronic inflammatory state and the development 
of autoimmune diseases [186, 187]. For example, accumulation of non-processed DNA 
from apoptotic cells results in Sting-dependent overproduction of type I IFNs [186-189].  
 
 Discussion 
 
 86          Identification of molecular mechanisms mediating the adjuvanticity of cyclic di-nucleotides 
The c-di-AMP has been shown to induce IFN-β locally in the area of application and not 
systemically [153]. In addition, Sting is down-regulated after CDN treatment of APCs 
(Rueckert, unpublished data). Both observations may point to mechanisms ensuring 
host homeostasis and preventing the overproduction of inflammatory cytokines.  
Translation of the findings related to Sting signaling from mouse to humans can be 
hampered by different sequences of human and murine Sting. For example, 
therapeutics acting via Sting, such as the antiviral drug CMA (10-carboxymethyl-9-
acridanone) [190, 191] and the cancer therapeutic DMXAA (5,6-Dimetylxanthenone-4-
acetic acid) [192] were successfully developed in murine models, but failed in human 
trials due to inability of binding to human Sting. However, it has been shown that c-di-
AMP and cGAMP are able to activate human dendritic cells, implying their potential use 
in human vaccines [140, 153]. However, isoforms of human Sting with differential 
responsiveness to CDNs have been identified [193]. The prevalence of specific Sting 
haplotypes seems to be related to different ethnical backgrounds of individuals, as 
reported in a study where haplotypes of 1090 individuals were analyzed [193]. 
Therefore, it has to be expected that the responsiveness to CDN-adjuvanted vaccines in 
specific geographical regions would be defined by the frequency of prevalent Sting 
haplotypes. For example, Yi et al. showed that in the group of individuals with European 
ethnical background alleles encoding CDN-responsive Sting are prevalent, whereas the 
frequency of the allele encoding the isoform not responding to CDN is around 15% 
[193]. Similar frequency of non-responding Sting isoform was observed in the group of 
individuals with African background, indicating the percentage of the population that 
probably would not respond to CDN-adjuvanted vaccines. Therefore, to ensure the 
protection throughout the population, alternative vaccination approaches would be 
needed to induce protective immune responses in individuals not being able to respond 
to CDN-containing vaccines. Alternatively, medicinal chemistry can be exploited to 
generate CDN derivatives able to stimulate all Sting isoforms.  
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5 CONCLUSIONS AND OUTLOOK 
The design of effective subunit vaccines requires availability of adjuvants capable of 
promoting humoral and cellular immune responses, not only systemically but also at the 
mucosal level. In this thesis it was demonstrated that the administration of cGAMP by 
i.n. route with the model antigen OVA to mice results in enhanced antigen-specific 
humoral responses at both systemic and mucosal level, as indicated by increased titers 
of serum IgG and mucosal IgA. In addition, it was observed an enhanced proliferation of 
splenocytes, as well as increment in the number of IFN-γ, IL-2, IL-4 and IL-17 producing 
cells. This, in turn indicates the capacity of cGAMP to induce balanced Th1/Th2/Th17 
responses. These findings suggest that cGAMP is a promising candidate adjuvant for 
the design of mucosal subunit vaccines.   
The adjuvant properties of c-di-AMP and cGAMP were then compared in mice. The 
obtained results showed that c-di-AMP is a more potent Th17 enhancer than cGAMP, 
whereas humoral and cellular responses were enhanced to a similar extent by the two 
CDNs. Collectively, these findings suggest that c-di-AMP and cGAMP can be used as 
tools for fine-tuning the Th17 responses, according to the specific clinical needs. For 
example, Th17 responses seem to be required for achieving efficient protection against 
pathogens such as M. tuberculosis and S. pneumonia [165, 194]. Further studies will be 
needed in order to assert the real value of c-di-AMP and cGAMP as adjuvants in terms 
of safety and efficacy for human vaccine in clinical trials. However the overall capacity of 
CDNs to promote both humoral and cellular responses to a similar extent appeals as 
extremely attractive for vaccine development. In fact, currently available adjuvants 
mainly promote humoral responses and there are few candidate adjuvants promoting 
the elicitation of both, cellular and humoral immunity [195]. Adjuvants promoting both, 
humoral and cellular responses would be key tools for the development of vaccines 
against persistent intracellular pathogens. In this particular setting, it would be essential 
to promote Th1 cell-facilitated CTL responses, which are able to kill infected cells. To 
further enhance the immune activity against intracellular pathogens, Th2 cell-potentiated 
humoral responses can be induced to inactivate the agents released from infected cells 
before they are able to enter bystander cells [196].  
An up-regulated expression of MHC class II and CD86, together with an increased 
production of type I IFNs and IL-12/IL-23p40 was observed after BMDC treatment with 
c-di-AMP or cGAMP. These parameters can be used as readouts for future in vitro 
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studies using specific inhibitors of potentially involved pathways that may be triggered by 
CDNs to explore signaling cascades involved in the adjuvant activity of CDNs. 
Comparative studies revealed that c-di-AMP is a more potent inducer of IL-12/IL-23p40 
production than cGAMP. This raises the question if their differential potencies to 
enhance a Th17 response in vivo may result from their differential induction of these 
cytokines. To this end, further experiments should elucidate if IL-12, IL-23 or just 
monomers or dimers of p40 are differentially up-regulated and if this contributes to the 
differential activation of Th17 responses.   
Type I IFN induction and signaling pathways were tested as mediators of the 
adjuvanticity of c-di-AMP and cGAMP. The c-di-AMP- and cGAMP-mediated 
enhancement of antigen-specific IgG responses, spleen cell proliferation and cytokine 
production were impaired in the animals lacking functional Sting, but not in mice lacking 
IFNAR. This led to the conclusion that the adjuvant effects of c-di-AMP and cGAMP are 
Sting-dependent, whereas IFNAR seems to be largely dispensable for adjuvanticity. 
However, IFNAR-mediated signaling seems to modulate the stimulated responses. For 
example, IFNAR seems to be required for a robust stimulation of IFN-γ responses 
enhanced by cGAMP. Future investigation may be designed to identify signaling 
pathway(s) triggered by Sting that are responsible for the CDN-mediated enhancement 
of adaptive immune responses. Those studies should define the pathways responsible 
for the residual adjuvant activity of c-di-GMP observed in animals lacking signaling via 
TBK-1-dependent non-canonical NF-κB-TNF-α pathway, as well as the mechanisms 
responsible for CTL priming and stimulation of long term memory responses.  
The identification of Sting as a key molecule mediating the adjuvanticity of c-di-AMP and 
cGAMP presented here and its differential responsiveness to CDNs in specific ethnical 
groups of human population [193] illustrate that integration of the knowledge about 
molecular mode of action of candidate adjuvants and population genetics may be 
potentially exploited for prediction of the efficacy of candidate vaccines in specific 
geographical regions. For this reason, the results presented in this thesis demonstrate 
that experimental concept of investigating molecular mode of action of candidate 
adjuvants represents a valuable approach in future research strategies that aim at 
rational vaccine design. 
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